Diabetes & Metabolism Journal

Brief Report

Technology/Device
Effectiveness of Predicted Low-Glucose Suspend Pump Technology in the Prevention of Hypoglycemia in People with Type 1 Diabetes Mellitus: Real-World Data Using DIA:CONN G8: Jee Hee Yoo, Ji Yoon Kim, Jae Hyeon Kim; Received January 24, 2024 Accepted March 29, 2024 Published online August 28, 2024; DOI: https://doi.org/10.4093/dmj.2024.0039 [Epub ahead of print]

427 View
26 Download

Abstract PDF Supplementary Material PubReader ePub: We evaluated the effectiveness of the predictive low-glucose suspend (PLGS) algorithm in the DIA:CONN G8. Forty people with type 1 diabetes mellitus (T1DM) who used a DIA:CONN G8 for at least 2 months with prior experience using pumps without and with PLGS were retrospectively analyzed. The objective was to assess the changes in time spent in hypoglycemia (percent of time below range [%TBR]) before and after using PLGS. The mean age, sensor glucose levels, glucose threshold for suspension, and suspension time were 31.1±22.8 years, 159.7±23.2 mg/dL, 81.1±9.1 mg/dL, and 111.9±79.8 min/day, respectively. Overnight %TBR <70 mg/dL was significantly reduced after using the algorithm (differences=0.3%, from 1.4%±1.5% to 1.1%±1.2%, P=0.045). The glycemia risk index (GRI) improved significantly by 4.2 (from 38.8±20.9 to 34.6±19.0, P=0.002). Using the PLGS did not result in a change in the hyperglycemia metric (all P>0.05). Our findings support the PLGS in DIA:CONN G8 as an effective algorithm to improve night-time hypoglycemia and GRI in people with T1DM.

Original Articles

Type 1 Diabetes
Optimal Coefficient of Variance Threshold to Minimize Hypoglycemia Risk in Individuals with Well-Controlled Type 1 Diabetes Mellitus: Jee Hee Yoo, Seung Hee Yang, Sang-Man Jin, Jae Hyeon Kim; Diabetes Metab J. 2024;48(3):429-439. Published online March 4, 2024; DOI: https://doi.org/10.4093/dmj.2023.0083

2,043 View
230 Download

Abstract PDF Supplementary Material PubReader ePub: Background
This study investigated the optimal coefficient of variance (%CV) for preventing hypoglycemia based on real-time continuous glucose monitoring (rt-CGM) data in people with type 1 diabetes mellitus (T1DM) already achieving their mean glucose (MG) target.
Methods
Data from 172 subjects who underwent rt-CGM for at least 90 days and for whom 439 90-day glycemic profiles were available were analyzed. Receiver operator characteristic analysis was conducted to determine the cut-off value of %CV to achieve time below range (%TBR)^{<54 mg/dL} <1 and =0.
Results
Overall mean glycosylated hemoglobin was 6.8% and median %TBR^{<54 mg/dL} was 0.2%. MG was significantly higher and %CV significantly lower in profiles achieving %TBR^{<54 mg/dL} <1 compared to %TBR^{<54 mg/dL} ≥1 (all P<0.001). The cut-off value of %CV for achieving %TBR^{<54 mg/dL} <1 was 37.5%, 37.3%, and 31.0%, in the whole population, MG >135 mg/dL, and ≤135 mg/dL, respectively. The cut-off value for %TBR^{<54 mg/dL}=0% was 29.2% in MG ≤135 mg/dL. In profiles with MG ≤135 mg/dL, 94.2% of profiles with a %CV <31 achieved the target of %TBR^{<54 mg/dL} <1, and 97.3% with a %CV <29.2 achieved the target of %TBR<54 mg/ dL=0%. When MG was >135 mg/dL, 99.4% of profiles with a %CV <37.3 achieved %TBR^{<54 mg/dL} <1.
Conclusion
In well-controlled T1DM with MG ≤135 mg/dL, we suggest a %CV <31% to achieve the %TBR^{<54 mg/dL} <1 target. Furthermore, we suggest a %CV <29.2% to achieve the target of %TBR^{<54 mg/dL} =0 for people at high risk of hypoglycemia.

Drug/Regimen
Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus: Shinae Kang, Yu-Bae Ahn, Tae Keun Oh, Won-Young Lee, Sung Wan Chun, Boram Bae, Amine Dahaoui, Jin Sook Jeong, Sungeun Jung, Hak Chul Jang; Diabetes Metab J. 2024;48(5):929-936. Published online February 27, 2024; DOI: https://doi.org/10.4093/dmj.2023.0297

1,796 View
133 Download

Abstract PDF Supplementary Material PubReader ePub: Background
This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp.
Methods
This was a multicenter, retrospective, observational study comprising two 26-week treatment periods, before and after switching to IDegAsp, respectively. Korean adults with uncontrolled T2DM treated with basal or premix insulin (±oral antidiabetic drugs) were enrolled. The primary objective was to compare the degree of glycosylated hemoglobin (HbA1c) change in each 26-week observation period. The analyses included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily insulin dose (ClinicalTrials.gov, number NCT04656106).
Results
In total, 196 adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. The change in both HbA1c and FPG were significantly different between the pre-switching and the post-switching period (0.28% vs. –0.51%, P<0.001; 5.21 mg/dL vs. –23.10 mg/dL, P=0.005), respectively. After switching, the rate of achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% with IDegAsp, P=0.012). No significant differences (before vs. after switching) were observed in body weight change, and total daily insulin dose. The rates of overall and severe hypoglycemia were similar in the two periods.
Conclusion
In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin.

Review

Cardiovascular Risk/Epidemiology
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus: Takayoshi Sasako, Toshimasa Yamauchi, Kohjiro Ueki; Diabetes Metab J. 2023;47(2):185-197. Published online January 12, 2023; DOI: https://doi.org/10.4093/dmj.2022.0325

6,818 View
404 Download
13 Web of Science
13 Crossref

Abstract PDF PubReader ePub

In the management of diabetes mellitus, one of the most important goals is to prevent its micro- and macrovascular complications, and to that end, multifactorial intervention is widely recommended. Intensified multifactorial intervention with pharmacotherapy for associated risk factors, alongside lifestyle modification, was first shown to be efficacious in patients with microalbuminuria (Steno-2 study), then in those with less advanced microvascular complications (the Anglo-Danish-Dutch Study of Intensive Treatment In People with Screen Detected Diabetes in Primary Care [ADDITION]-Europe and the Japan Diabetes Optimal Treatment study for 3 major risk factors of cardiovascular diseases [J-DOIT3]), and in those with advanced microvascular complications (the Nephropathy In Diabetes-Type 2 [NID-2] study and Diabetic Nephropathy Remission and Regression Team Trial in Japan [DNETT-Japan]). Thus far, multifactorial intervention led to a reduction in cardiovascular and renal events, albeit not necessarily significant. It should be noted that not only baseline characteristics but also the control status of the risk factors and event rates during intervention among the patients widely varied from one trial to the next. Further evidence is needed for the efficacy of multifactorial intervention in a longer duration and in younger or elderly patients. Moreover, now that new classes of antidiabetic drugs are available, it should be addressed whether strict and safe glycemic control, alongside control of other risk factors, could lead to further risk reductions in micro- and macrovascular complications, thereby decreasing all-cause mortality in patients with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by

Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications
Takayoshi Sasako
Diabetology International.2024; 15(1): 34. CrossRef
Targeting ERS-mitophagy in hippocampal neurons to explore the improvement of memory by tea polyphenols in aged type 2 diabetic rats
Wenjuan Feng, Chenhui Lv, Le Cheng, Xin Song, Xuemin Li, Haoran Xie, Shuangzhi Chen, Xi Wang, Lushan Xue, Cheng Zhang, Jie Kou, Lili Wang, Haifeng Zhao
Free Radical Biology and Medicine.2024; 213: 293. CrossRef
Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program
Kailu Wang, Shi Zhao, Eric Kam-Pui Lee, Susan Zi-May Yau, Yushan Wu, Chi-Tim Hung, Eng-Kiong Yeoh
JAMA Network Open.2024; 7(2): e2355733. CrossRef
Causes of In-Hospital Death and Pharmaceutical Associations with Age of Death during a 10-Year Period (2011–2020) in Individuals with and without Diabetes at a Japanese Community General Hospital
Minae Hosoki, Taiki Hori, Yousuke Kaneko, Kensuke Mori, Saya Yasui, Seijiro Tsuji, Hiroki Yamagami, Saki Kawata, Tomoyo Hara, Shiho Masuda, Yukari Mitsui, Kiyoe Kurahashi, Takeshi Harada, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Itsur
Journal of Clinical Medicine.2024; 13(5): 1283. CrossRef
External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance
Camilla Sammut-Powell, Rose Sisk, Ruben Silva-Tinoco, Gustavo de la Pena, Paloma Almeda-Valdes, Sonia Citlali Juarez Comboni, Susana Goncalves, Rory Cameron
Frontiers in Endocrinology.2024;[Epub] CrossRef
Gut Microbiota Targeted Approach by Natural Products in Diabetes Management: An Overview
Priyanka Sati, Praveen Dhyani, Eshita Sharma, Dharam Chand Attri, Arvind Jantwal, Rajni Devi, Daniela Calina, Javad Sharifi-Rad
Current Nutrition Reports.2024; 13(2): 166. CrossRef
Lipids as potential mediators linking body mass index to diabetes: evidence from a mediation analysis based on the NAGALA cohort
Song Lu, Qun Wang, Hengcheng Lu, Maobin Kuang, Min Zhang, Guotai Sheng, Yang Zou, Xiaoping Peng
BMC Endocrine Disorders.2024;[Epub] CrossRef
Potential of FGF21 in type 2 diabetes mellitus treatment based on untargeted metabolomics
Shuai Li, Zilong Song, Chunxiang Fan, Weiwei Zhang, Tianyi Ma, Xu Li, Qi Zhang, Ming Zhao, Tianfei Yu, Shanshan Li
Biochemical Pharmacology.2024; 225: 116306. CrossRef
Exploring mechanisms of insulin action and strategies to treat diabetes
Takayoshi Sasako
Endocrine Journal.2024; 71(7): 651. CrossRef
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso
Biomedicines.2024; 12(9): 2039. CrossRef
The gaps between the guidelines definitions and routine of care adopted in primary health care regarding diabetes kidney disease: a real-life study
Silvia Ferreira Bortoto, Jacira Xavier de Carvalho, Mozania Reis de Matos, Cristiane das Graças Dias Cavalcante, Elenilda Almeida Silva Andrade, Márcia Silva Queiroz
Journal of Public Health.2024;[Epub] CrossRef
Cardiovascular Risk Reduction in Type 2 Diabetes: Further Insights into the Power of Weight Loss and Exercise
Seung-Hwan Lee
Endocrinology and Metabolism.2023; 38(3): 302. CrossRef
Sarcopenia: Loss of mighty armor against frailty and aging
Takayoshi Sasako, Kohjiro Ueki
Journal of Diabetes Investigation.2023; 14(10): 1145. CrossRef

Original Articles

Type 1 Diabetes
Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis: Deep Dutta, Ritin Mohindra, Kunal Mahajan, Meha Sharma; Diabetes Metab J. 2023;47(1):72-81. Published online June 24, 2022; DOI: https://doi.org/10.4093/dmj.2022.0035

6,013 View
268 Download
1 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events.
Results
Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], –1.35 mmol/L; 95% confidence interval [CI], –1.72 to –0.98; P<0.01; I²=63%) and 2hPPG (MD, –1.19 mmol/L; 95% CI, –1.38 to –1.00; P<0.01; I²=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, –3.84 to 5.96; P=0.67; I²=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, –0.91%; 95% CI, –1.84 to 0.03; P=0.06; I²=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; P=0.51; I²=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; P=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; P=0.77; I²=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; P=0.50; I²=0%) were comparable.
Conclusion
FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.

Citations

Citations to this article as recorded by

Burden and Coping Strategies of Hypoglycemia in People with Diabetes
Aris Liakos, Thomas Karagiannis, Ioannis Avgerinos, Apostolos Tsapas, Eleni Bekiari
Current Diabetes Reviews.2024;[Epub] CrossRef
Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects
L. A. Suplotova, A. Sh. Tilkiyan
Meditsinskiy sovet = Medical Council.2024; (13): 146. CrossRef
Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467. CrossRef

Metabolic Risk/Epidemiology
Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus: Soyeon Kang, Yong-Moon Park, Dong Jin Kwon, Youn-Jee Chung, Jeong Namkung, Kyungdo Han, Seung-Hyun Ko; Diabetes Metab J. 2022;46(4):578-591. Published online January 24, 2022; DOI: https://doi.org/10.4093/dmj.2021.0135

8,005 View
246 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Estrogen promotes glucose homeostasis, enhances insulin sensitivity, and maintains counterregulatory responses in recurrent hypoglycemia in women of reproductive age. Postmenopausal women with type 2 diabetes mellitus (T2DM) might be more vulnerable to severe hypoglycemia (SH) events. However, the relationship between reproductive factors and SH occurrence in T2DM remains unelucidated.
Methods
This study included data on 181,263 women with postmenopausal T2DM who participated in a national health screening program from January 1 to December 31, 2009, obtained using the Korean National Health Insurance System database. Outcome data were obtained until December 31, 2018. Associations between reproductive factors and SH incidence were assessed using Cox proportional hazards models.
Results
During the mean follow-up of 7.9 years, 11,279 (6.22%) postmenopausal women with T2DM experienced SH episodes. A longer reproductive life span (RLS) (≥40 years) was associated with a lower SH risk compared to a shorter RLS (<30 years) (adjusted hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.69 to 0.80; P for trend <0.001) after multivariable adjustment. SH risk decreased with every 5-year increment of RLS (with <30 years as a reference [adjusted HR, 0.91; 95% CI, 0.86 to 0.95; P=0.0001 for 30−34 years], [adjusted HR, 0.80; 95% CI, 0.76 to 0.84; P<0.001 for 35−39 years], [adjusted HR, 0.74; 95% CI, 0.68 to 0.81; P<0.001 for ≥40 years]). The use of hormone replacement therapy (HRT) was associated with a lower SH risk than HRT nonuse.
Conclusion
Extended exposure to endogenous ovarian hormone during lifetime may decrease the number of SH events in women with T2DM after menopause.

Citations

Citations to this article as recorded by

Association between serum copper level and reproductive health of Women in the United States: a cross-sectional study
Yi Yuan, Tong-Yu Peng, Guang-Yuan Yu, Zhao Zou, Meng-Ze Wu, Ruofei Zhu, Shuang Wu, Zi Lv, Su-Xin Luo
International Journal of Environmental Health Research.2024; 34(6): 2441. CrossRef
Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes
Nicole L Spartano, Naznin Sultana, Honghuang Lin, Huimin Cheng, Sophia Lu, David Fei, Joanne M Murabito, Maura E Walker, Howard A Wolpert, Devin W Steenkamp
The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Reproductive Lifespan and Motor Progression of Parkinson’s Disease
Ruwei Ou, Qianqian Wei, Yanbing Hou, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Tianmi Yang, Jing Yang, Zheng Jiang, Wei Song, Bei Cao, Huifang Shang
Journal of Clinical Medicine.2022; 11(20): 6163. CrossRef
Menopause and development of Alzheimer’s disease: Roles of neural glucose metabolism and Wnt signaling
Paulina Villaseca, Pedro Cisternas, Nibaldo C. Inestrosa
Frontiers in Endocrinology.2022;[Epub] CrossRef

Review

Technology/Device
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence: Sun Joon Moon, Inha Jung, Cheol-Young Park; Diabetes Metab J. 2021;45(6):813-839. Published online November 22, 2021; DOI: https://doi.org/10.4093/dmj.2021.0177

17,112 View
887 Download
40 Web of Science
39 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.

Citations

Citations to this article as recorded by

Integration of a Safety Module to Prevent Rebound Hypoglycemia in Closed-Loop Artificial Pancreas Systems
María F. Villa-Tamayo, Patricio Colmegna, Marc D. Breton
Journal of Diabetes Science and Technology.2024; 18(2): 318. CrossRef
The effects of acute hyperglycaemia on sports and exercise performance in type 1 diabetes: A systematic review and meta-analysis
Bonar McGuire, Hashim Dadah, Dominic Oliver
Journal of Science and Medicine in Sport.2024; 27(2): 78. CrossRef
A new approach to stabilize diabetes systems with time-varying delays and disturbance rejection
S. Syafiie, Fahd Alharbi, Abdullah Ali Alshehri, Bassam Hasanain
Journal of the Franklin Institute.2024; 361(1): 543. CrossRef
Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs
Ingrid Anna Teigen, Marte Kierulf Åm, Misbah Riaz, Sverre Christian Christiansen, Sven Magnus Carlsen
Current Therapeutic Research.2024; 100: 100736. CrossRef
Enhancing equity in access to automated insulin delivery systems in an ethnically and socioeconomically diverse group of children with type 1 diabetes
John Pemberton, Louise Collins, Lesley Drummond, Renuka P Dias, Ruth Krone, Melanie Kershaw, Suma Uday
BMJ Open Diabetes Research & Care.2024; 12(3): e004045. CrossRef
Robust Online Correlation Method for Identification of a Nonparametric Model of Type 1 Diabetes
Martin Dodek, Eva Miklovičová
IEEE Access.2024; 12: 35899. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial
Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim
Diabetologia.2024; 67(7): 1235. CrossRef
Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Maria Luisa Garo, Donatella Pastore, Francesca Pacifici, Camillo Ricordi, David Della-Morte, Marco Infante
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions
Giulia Bennici, Hanan Almahasheer, Mawadda Alghrably, Daniela Valensin, Arian Kola, Chrysoula Kokotidou, Joanna Lachowicz, Mariusz Jaremko
RSC Advances.2024; 14(25): 17448. CrossRef
Real‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Qin Yang, Baoqi Zeng, Jiayi Hao, Qingqing Yang, Feng Sun
Diabetes, Obesity and Metabolism.2024; 26(9): 3753. CrossRef
Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study
Marta Bassi, Daniele Franzone, Francesca Dufour, Giordano Spacco, Federico Cresta, Giuseppe d’Annunzio, Giacomo Tantari, Maria Grazia Calevo, Carlo Castellani, Nicola Minuto, Rosaria Casciaro
Frontiers in Endocrinology.2024;[Epub] CrossRef
Emerging Technologies in Endocrine Drug Delivery: Innovations for Improved Patient Care
Mahvish Renzu, Carly Hubers, Kendall Conway, Viktoriya Gibatova, Vidhi Mehta, Wael Taha
Cureus.2024;[Epub] CrossRef
A stochastic model-based control methodology for glycemic management in the intensive care unit
Melike Sirlanci, George Hripcsak, Cecilia C. Low Wang, J. N. Stroh, Yanran Wang, Tellen D. Bennett, Andrew M. Stuart, David J. Albers
Frontiers in Medical Engineering.2024;[Epub] CrossRef
Advances in Type 1 Diabetes Mellitus Management in Children
Mridu Bahal, Vineeta Pande, Jasleen Dua, Shailaja Mane
Cureus.2024;[Epub] CrossRef
Expansion of the Pancreas Transplant Recipient Pool: Appropriate for Most or Are There Limits?
Jonathan A. Fridell, Robert J. Stratta
Current Transplantation Reports.2024;[Epub] CrossRef
Reinforcement Learning: A Paradigm Shift in Personalized Blood Glucose Management for Diabetes
Lehel Dénes-Fazakas, László Szilágyi, Levente Kovács, Andrea De Gaetano, György Eigner
Biomedicines.2024; 12(9): 2143. CrossRef
100 Years of insulin: A chemical engineering perspective
B. Wayne Bequette
Korean Journal of Chemical Engineering.2023; 40(1): 1. CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park
Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Identifiable prediction animal model for the bi-hormonal intraperitoneal artificial pancreas
Karim Davari Benam, Hasti Khoshamadi, Marte Kierulf Åm, Øyvind Stavdahl, Sebastien Gros, Anders Lyngvi Fougner
Journal of Process Control.2023; 121: 13. CrossRef
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2023; 47(1): 27. CrossRef
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review
John S Pemberton, Emma G Wilmot, Katharine Barnard‐Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
Diabetes, Obesity and Metabolism.2023; 25(4): 916. CrossRef
Evaluation of awareness and attitude of paediatric nursing students, nurses, and adolescents regarding type one diabetes advanced devices and virtual nursing
Howaida Moawad Ahmed Ali
Kontakt.2023; 25(2): 100. CrossRef
Predicting the output error of the suboptimal state estimator to improve the performance of the MPC-based artificial pancreas
Martin Dodek, Eva Miklovičová
Control Theory and Technology.2023; 21(4): 541. CrossRef
A Markov Model of Gap Occurrence in Continuous Glucose Monitoring Data for Realistic in Silico Clinical Trials
Martina Vettoretti, Martina Drecogna, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Computer Methods and Programs in Biomedicine.2023; 240: 107700. CrossRef
Drug delivery breakthrough technologies – A perspective on clinical and societal impact
Beate Bittner, Manuel Sánchez-Félix, Dennis Lee, Athanas Koynov, Joshua Horvath, Felix Schumacher, Simon Matoori
Journal of Controlled Release.2023; 360: 335. CrossRef
Importance of continuous glucose monitoring in the treatment of diabetes mellitus
Sun Joon Moon, Won-Young Lee
Journal of the Korean Medical Association.2023; 66(7): 432. CrossRef
Constrained Versus Unconstrained Model Predictive Control for Artificial Pancreas
Chiara Toffanin, Lalo Magni
IEEE Transactions on Control Systems Technology.2023; 31(5): 2288. CrossRef
Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?
Valentina Maria Cambuli, Marco Giorgio Baroni
International Journal of Molecular Sciences.2023; 24(17): 13139. CrossRef
Artificial Intelligence in Efficient Diabetes Care
Gopal Bhagwan Khodve, Sugato Banerjee
Current Diabetes Reviews.2023;[Epub] CrossRef
The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control
M. K. Åm, I. A. Teigen, M. Riaz, A. L. Fougner, S. C. Christiansen, S. M. Carlsen
Journal of Endocrinological Investigation.2023; 47(3): 513. CrossRef
Multivariable Automated Insulin Delivery System for Handling Planned and Spontaneous Physical Activities
Mohammad Reza Askari, Mohammad Ahmadasas, Andrew Shahidehpour, Mudassir Rashid, Laurie Quinn, Minsun Park, Ali Cinar
Journal of Diabetes Science and Technology.2023; 17(6): 1456. CrossRef
Advanced Technology (Continuous Glucose Monitoring and Advanced Hybrid Closed-Loop Systems) in Diabetes from the Perspective of Gender Differences
Maria Grazia Nuzzo, Marciano Schettino
Diabetology.2023; 4(4): 519. CrossRef
Artificial Pancreas under a Zone Model Predictive Control based on Gaussian Process models: toward the personalization of the closed loop
Marco Polver, Beatrice Sonzogni, Mirko Mazzoleni, Fabio Previdi, Antonio Ferramosca
IFAC-PapersOnLine.2023; 56(2): 9642. CrossRef
Personalized Constrained MPC for glucose regulation
Chiara Toffanin, Lalo Magni
IFAC-PapersOnLine.2023; 56(2): 9648. CrossRef
Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-analysis of Outpatient Randomized Controlled Trials
Baoqi Zeng, Le Gao, Qingqing Yang, Hao Jia, Feng Sun
Diabetes Care.2023; 46(12): 2300. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis
Baoqi Zeng, Hao Jia, Le Gao, Qingqing Yang, Kai Yu, Feng Sun
Diabetes, Obesity and Metabolism.2022; 24(10): 1967. CrossRef
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Alezandra Torres-Castaño, Amado Rivero-Santana, Lilisbeth Perestelo-Pérez, Andrea Duarte-Díaz, Analia Abt-Sacks, Vanesa Ramos-García, Yolanda Álvarez-Pérez, Ana M. Wäagner, Mercedes Rigla, Pedro Serrano-Aguilar
Applied Sciences.2022; 12(20): 10262. CrossRef
History of insulin treatment of pediatric patients with diabetes in Korea
Jae Hyun Kim, Choong Ho Shin, Sei Won Yang
Annals of Pediatric Endocrinology & Metabolism.2021; 26(4): 237. CrossRef

Original Article

Drug/Regimen
Efficacy and Safety of Self-Titration Algorithms of Insulin Glargine 300 units/mL in Individuals with Uncontrolled Type 2 Diabetes Mellitus (The Korean TITRATION Study): A Randomized Controlled Trial: Jae Hyun Bae, Chang Ho Ahn, Ye Seul Yang, Sun Joon Moon, Soo Heon Kwak, Hye Seung Jung, Kyong Soo Park, Young Min Cho; Diabetes Metab J. 2022;46(1):71-80. Published online June 16, 2021; DOI: https://doi.org/10.4093/dmj.2020.0274

10,115 View
463 Download
2 Web of Science
4 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Background
To compare the efficacy and safety of two insulin self-titration algorithms, Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment (INSIGHT) and EDITION, for insulin glargine 300 units/mL (Gla-300) in Korean individuals with uncontrolled type 2 diabetes mellitus (T2DM).
Methods
In a 12-week, randomized, open-label trial, individuals with uncontrolled T2DM requiring basal insulin were randomized to either the INSIGHT (adjusted by 1 unit/day) or EDITION (adjusted by 3 units/week) algorithm to achieve a fasting self-monitoring of blood glucose (SMBG) in the range of 4.4 to 5.6 mmol/L. The primary outcome was the proportion of individuals achieving a fasting SMBG ≤5.6 mmol/L without noct urnal hypoglycemia at week 12.
Results
Of 129 individuals (age, 64.1±9.5 years; 66 [51.2%] women), 65 and 64 were randomized to the INSIGHT and EDITION algorithms, respectively. The primary outcome of achievement was comparable between the two groups (24.6% vs. 23.4%, P=0.876). Compared with the EDITION group, the INSIGHT group had a greater reduction in 7-point SMBG but a similar decrease in fasting plasma glucose and glycosylated hemoglobin. The increment of total daily insulin dose was significantly higher in the INSIGHT group than in the EDITION group (between-group difference: 5.8±2.7 units/day, P=0.033). However, body weight was significantly increased only in the EDITION group (0.6±2.4 kg, P=0.038). There was no difference in the occurrence of hypoglycemia between the two groups. Patient satisfaction was significantly increased in the INSIGHT group (P=0.014).
Conclusion
The self-titration of Gla-300 using the INSIGHT algorithm was effective and safe compared with that using the EDITION algorithm in Korean individuals with uncontrolled T2DM (ClinicalTrials.gov number: NCT03406663).

Citations

Citations to this article as recorded by

Time for Using Machine Learning for Dose Guidance in Titration of People With Type 2 Diabetes? A Systematic Review of Basal Insulin Dose Guidance
Camilla Heisel Nyholm Thomsen, Stine Hangaard, Thomas Kronborg, Peter Vestergaard, Ole Hejlesen, Morten Hasselstrøm Jensen
Journal of Diabetes Science and Technology.2024; 18(5): 1185. CrossRef
Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta‐analysis of randomized clinical trials
Hazem Ayesh, Sajida Suhail, Suhail Ayesh, Kevin Niswender
Diabetes, Obesity and Metabolism.2024; 26(9): 3801. CrossRef
Basal insulin titration algorithms in patients with type 2 diabetes: the simplest is the best (?)
V.I. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(1): 72. CrossRef
Issues of insulin therapy for type 2 diabetes and ways to solve them
V.I. Katerenchuk, A.V. Katerenchuk
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(3): 240. CrossRef

Review

Type 1 Diabetes
Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis: Xiaoling Cai, Chu Lin, Wenjia Yang, Lin Nie, Linong Ji; Diabetes Metab J. 2021;45(3):312-325. Published online March 15, 2021; DOI: https://doi.org/10.4093/dmj.2020.0171

6,961 View
293 Download
5 Web of Science
5 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

In order to evaluate the efficacy and side effects of the non-insulin antidiabetes medications as an adjunct treatment in type 1 diabetes mellitus (T1DM), we conducted systematic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between the date of inception and March 2020 to produce a systematic review and meta-analysis. Overall, 57 studies were included. Compared with placebo, antidiabetes agents in adjunct to insulin treatment resulted in significant reduction in glycosylated hemoglobin (weighted mean difference [WMD], –0.30%; 95% confidence interval [CI], –0.34 to –0.25%; P<0.01) and body weight (WMD, –2.15 kg; 95% CI, –2.77 to –1.53 kg; P<0.01), and required a significantly lower dosage of insulin (WMD, –5.17 unit/day; 95% CI, –6.77 to –3.57 unit/day; P<0.01). Compared with placebo, antidiabetes agents in adjunct to insulin treatment increased the risk of hypoglycemia (relative risk [RR], 1.04; 95% CI, 1.01 to 1.08; P=0.02) and gastrointestinal side effects (RR, 1.99; 95% CI, 1.61 to 2.46; P<0.01) in patients with T1DM. Compared with placebo, the use of non-insulin antidiabetes agents in addition to insulin could lead to glycemic improvement, weight control and lower insulin dosage, while they might be associated with increased risks of hypoglycemia and gastrointestinal side effects in patients with T1DM.

Citations

Citations to this article as recorded by

Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists
Patrice Forner, Jennifer Snaith, Jerry R. Greenfield
Internal Medicine Journal.2024; 54(5): 779. CrossRef
Dioscin: Therapeutic potential for diabetes and complications
Haoyang Gao, Ze Wang, Danlin Zhu, Linlin Zhao, Weihua Xiao
Biomedicine & Pharmacotherapy.2024; 170: 116051. CrossRef
The Impact of Body Mass Index, Residual Beta Cell Function and Estimated Glucose Disposal Rate on the Development of Double Diabetes and Microvascular Complications in Patients With Type 1 Diabetes Mellitus
Rameez Raja Bhagadurshah, Subbiah Eagappan, Raghavan Kasthuri Santharam, Sridhar Subbiah
Cureus.2023;[Epub] CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science.2021; 373(6554): 522. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Sun Joon Moon, Inha Jung, Cheol-Young Park
Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef

Original Articles

Complications
Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence: Jeongmin Lee, Tong Min Kim, Hyunah Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim; Diabetes Metab J. 2020;44(4):555-565. Published online May 8, 2020; DOI: https://doi.org/10.4093/dmj.2019.0064

7,316 View
117 Download
8 Web of Science
9 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Some patients admitted to hospitals for glycemic control experience hypoglycemia despite regular meals and despite adhering to standard blood glucose control protocols. Different factors can have a negative impact on blood glucose control and prognosis after discharge. This study investigated risk factors for hypoglycemia and its effects on glycemic control during the hospitalization of patients in the general ward.

Methods

This retrospective study included patients who were admitted between 2009 and 2018. Patients were provided regular meals at fixed times according to ideal body weights during hospitalization. We categorized the patients into two groups: those with and those without hypoglycemia during hospitalization.

Results

Of the 3,031 patients, 379 experienced at least one episode of hypoglycemia during hospitalization (HYPO group). Hypoglycemia occurred more frequently particularly in cases of premixed insulin therapy. Compared with the control group, the HYPO group was older (61.0±16.8 years vs. 59.1±16.5 years, P=0.035), with more females (60.4% vs. 49.6%, P<0.001), lower body mass index (BMI) (23.5±4.2 kg/m² vs. 25.1±4.4 kg/m², P<0.001), and higher prevalence of type 1 diabetes mellitus (6.1% vs. 2.6%, P<0.001), They had longer hospital stay (11.1±13.5 days vs. 7.6±4.6 days, P<0.001). After discharge the HYPO group had lower glycosylated hemoglobin reduction rate (−2.0%±0.2% vs. −2.5%±0.1%, P=0.003) and tended to have more frequent cases of cardiovascular disease.

Conclusion

Hypoglycemia occurred more frequently in older female patients with lower BMI and was associated with longer hospital stay and poorer glycemic control after discharge. Therefore, clinicians must carefully ensure that patients do not experience hypoglycemia during hospitalization.

Citations

Citations to this article as recorded by

Hypoglycemia in hospitalized patients: A sleeping monster
Swarna Deepak Kuragayala, Sumita Nayak, Khalid Khatib
Muller Journal of Medical Sciences and Research.2024; 15(1): 5. CrossRef
Acute kidney injury: a strong risk factor for hypoglycaemia in hospitalized patients with type 2 diabetes
Ana Carreira, Pedro Castro, Filipe Mira, Miguel Melo, Pedro Ribeiro, Lèlita Santos
Acta Diabetologica.2023; 60(9): 1179. CrossRef
Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study
Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko
Journal of Diabetes Investigation.2022; 13(9): 1533. CrossRef
Predicting hypoglycemia in hospitalized patients with diabetes: A derivation and validation study
Michal Elbaz, Jeries Nashashibi, Shiri Kushnir, Leonard Leibovici
Diabetes Research and Clinical Practice.2021; 171: 108611. CrossRef
Hospital care: improving outcomes in type 1 diabetes
Schafer Boeder, Kristen Kulasa
Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(1): 14. CrossRef
Data Pseudonymization in a Range That Does Not Affect Data Quality: Correlation with the Degree of Participation of Clinicians
Soo-Yong Shin, Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Letter: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
Sung-Woo Kim
Diabetes & Metabolism Journal.2020; 44(5): 775. CrossRef
Response: Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence (Diabetes Metab J 2020;44:555-65)
Jeongmin Lee, Hun-Sung Kim
Diabetes & Metabolism Journal.2020; 44(5): 779. CrossRef
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2020; 26(43): 5637. CrossRef

Drug/Regimen
Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial: Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi; Diabetes Metab J. 2020;44(4):532-541. Published online November 22, 2019; DOI: https://doi.org/10.4093/dmj.2019.0093

6,515 View
172 Download
8 Web of Science
10 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes mellitus (T2DM).

Methods

In this multicenter, open-label, prospective, randomized, parallel-group comparison trial, participants on basal insulin therapy were switched to IDegAsp (IDegAsp group; n=30) or continued basal insulin (Basal group; n=29). The primary endpoint was the superiority of IDegAsp in causing changes in the daily blood glucose profile, especially post-prandial blood glucose concentration after 12 weeks.

Results

Blood glucose concentrations after dinner and before bedtime were lower in the IDegAsp group, and the improvement in blood glucose before bedtime was significantly greater in the IDegAsp group than in the Basal group at 12 weeks (−1.7±3.0 mmol/L vs. 0.3±2.1 mmol/L, P<0.05). Intriguingly, glycemic control after breakfast was not improved by IDegAsp injection before breakfast, in contrast to the favorable effect of injection before dinner on blood glucose after dinner. Glycosylated hemoglobin significantly decreased only in the IDegAsp group (58 to 55 mmol/mol, P<0.05). Changes in daily insulin dose, body mass, and recorded adverse effects, including hypoglycemia, were comparable between groups.

Conclusion

IDegAsp was more effective than basal insulin at reducing blood glucose after dinner and before bedtime, but did not increase the incidence of hypoglycemia. Switching from basal insulin to IDegAsp does not increase the burden on the patient and positively impacts glycemic control in patients with T2DM.

Citations

Citations to this article as recorded by

Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins
Joshua R. Walt, Julie Loughran, Spiros Fourlanos, Rahul D. Barmanray, Jasmine Zhu, Suresh Varadarajan, Mervyn Kyi
Internal Medicine Journal.2024; 54(8): 1329. CrossRef
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
Ming Liu, Weijun Gu, Li Chen, Yanbing Li, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du, Yiming Mu
Diabetes, Obesity and Metabolism.2024; 26(9): 3791. CrossRef
Cutting-edge microneedle innovations: Transforming the landscape of cardiovascular and metabolic disease management
Xiaoning Zhang, Ming Li, Qiang Gao, Xiaoya Kang, Jingyao Sun, Yao Huang, Hong Xu, Jing Xu, Songren Shu, Jian Zhuang, Yuan Huang
iScience.2024; 27(9): 110615. CrossRef
Low fasting glucose‐to‐estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes
Han Na Jang, Ye Seul Yang, Tae Jung Oh, Bo Kyung Koo, Seong Ok Lee, Kyong Soo Park, Hak Chul Jang, Hye Seung Jung
Journal of Diabetes Investigation.2022; 13(1): 85. CrossRef
Comparing Time to Intensification between insulin Degludec/Insulin Aspart and Insulin Glargine
Rajiv Kovil
Journal of Diabetology.2022; 13(2): 171. CrossRef
Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns
Tevfik Demir, Serap Turan, Kursad Unluhizarci, Oya Topaloglu, Tufan Tukek, Dilek Gogas Yavuz
Frontiers in Endocrinology.2021;[Epub] CrossRef
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
I. N. Dyakov, S. K. Zyryanov
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.2021; 20(1): 4. CrossRef
Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
Shinje Moon, Hye-Soo Chung, Yoon-Jung Kim, Jae-Myung Yu, Woo-Ju Jeong, Jiwon Park, Chang-Myung Oh
Metabolites.2021; 11(9): 639. CrossRef
Insulin therapy in diabetic kidney disease
Yan Liu, Chanyue Zhao, Xiaofen Xiong, Ming Yang, Lin Sun
Diabetic Nephropathy.2021; 1(2): 67. CrossRef
Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin
Anwar Ali Jammah
Primary Care Diabetes.2020;[Epub] CrossRef

Clinical Complications
Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study: Young-Gun Kim, Dong Gyu Park, So Young Moon, Ja Young Jeon, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Seung Jin Han; Diabetes Metab J. 2020;44(1):125-133. Published online October 23, 2019; DOI: https://doi.org/10.4093/dmj.2018.0260

7,392 View
219 Download
32 Web of Science
32 Crossref

Abstract PDF PubReader

Background

Type 2 diabetes mellitus (T2DM) is associated with an increased risk for dementia. The effects of hypoglycemia on dementia are controversial. Thus, we evaluated whether hypoglycemia increases the risk for dementia in senior patients with T2DM.

Methods

We used the Korean National Health Insurance Service Senior cohort, which includes >10% of the entire senior population of South Korea. In total, 5,966 patients who had ever experienced at least one episode of hypoglycemia were matched with those who had not, using propensity score matching. The risk of dementia was assessed through a survival analysis of matched pairs.

Results

Patients with underlying hypoglycemic events had an increased risk for all-cause dementia, Alzheimer's dementia (AD), and vascular dementia (VaD) compared with those who had not experienced a hypoglycemic event (hazard ratio [HR], 1.254; 95% confidence interval [CI], 1.166 to 1.349; P<0.001 for all-cause dementia; HR, 1.264; 95% CI, 1.162 to 1.375; P<0.001 for AD; HR, 1.286; 95% CI, 1.110 to 1.490; P<0.001 for VaD). According to number of hypoglycemic episodes, the HRs of dementia were 1.170, 1.201, and 1.358 in patients with one hypoglycemic episode, two or three episodes, and more than three episodes, respectively. In the subgroup analysis, hypoglycemia was associated with an increased risk for dementia in both sexes with or without T2DM microvascular or macrovascular complications.

Conclusion

Our findings suggest that patients with a history of hypoglycemia have a higher risk for dementia. This trend was similar for AD and VaD, the two most important subtypes of dementia.

Citations

Citations to this article as recorded by

Potential risk factors for mild cognitive impairment among patients with type 2 diabetes experiencing hypoglycemia
Ruonan Gao, Menglan Zhan, Sujie Ke, Kejun Wu, Guanlian He, Liqin Qi, Xiaoying Liu, Xiaohong Liu, Lijing Wang, Libin Liu
Diabetes Research and Clinical Practice.2024; 207: 111036. CrossRef
Association of hypoglycemic events with cognitive impairment in patients with type 2 diabetes mellitus: Protocol for a dose-response meta-analysis
Min Ye, Ai Hong Yuan, Qi Qi Yang, Qun Wei Li, Fei Yue Li, Yan Wei, Muhammad Shahzad Aslam
PLOS ONE.2024; 19(2): e0296662. CrossRef
AGE, DISEASE DURATION AND MULTIMORBIDITY AS PREDICTORS OF HYPOGLYCEMIA IN ELDERLY AND SENILE WOMEN WITH TYPE 2 DIABETES MELLITUS
Polina Ya. Merzlova, Svetlana V. Bulgakova, Dmitry P. Kurmaev, Ekaterina V. Treneva
Science and Innovations in Medicine.2024;[Epub] CrossRef
A nomogram for predicting the risk of cancer-related cognitive impairment in breast cancer patients based on a scientific symptom model
Zhongtao Zhou, Jiajia Ren, Qiankun Liu, Shuoshuo Li, Jiahui Xu, Xiaoyan Wu, Yuanxiang Xiao, Zipu Zhang, Wanchen Jia, Huaiyu Bai, Jing Zhang
Scientific Reports.2024;[Epub] CrossRef
Взаимосвязь гипогликемии и когнитивных нарушений у пожилых пациентов с сахарным диабетом 2 типа
S. V. Bulgakova, P. Ya. Merzlova, D. P. Kurmaev, E. V. Treneva
Russian Journal of Geriatric Medicine.2024; (2): 108. CrossRef
Effect of hypoglycemic events on cognitive function in individuals with type 2 diabetes mellitus: a dose–response meta-analysis
Min Ye, Qiqi Yang, Lele Zhang, Hudie Song, Qin Fu, Jun Qian, Hongyu Xie, Aihong Yuan
Frontiers in Neurology.2024;[Epub] CrossRef
Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling
Wajd Alkabbani, Colleen J Maxwell, Ruth Ann Marrie, Suzanne L Tyas, Iliana C Lega, John-Michael Gamble
International Journal of Epidemiology.2023; 52(3): 908. CrossRef
Type 2 diabetes mellitus and cognitive function: understanding the connections
Lisa Dao, Sarah Choi, Matthew Freeby
Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(1): 7. CrossRef
Associations of Mid- and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
Wajd Alkabbani, Colleen J. Maxwell, Ruth Ann Marrie, Suzanne L. Tyas, Iliana C. Lega, John-Michael Gamble
Diabetes Care.2023; 46(2): 331. CrossRef
Nocturnal hypoglycemia is underdiagnosed in older people with insulin‐treated type 2 diabetes: The HYPOAGE observational study
Anne‐Sophie Boureau, Béatrice Guyomarch, Pierre Gourdy, Ingrid Allix, Cédric Annweiler, Nathalie Cervantes, Guillaume Chapelet, Isabelle Delabrière, Sophie Guyonnet, Rachel Litke, Marc Paccalin, Alfred Penfornis, Pierre‐Jean Saulnier, Matthieu Wargny, Sam
Journal of the American Geriatrics Society.2023; 71(7): 2107. CrossRef
Dementia in Diabetes: The Role of Hypoglycemia
Khaled Hameed Husain, Saud Faisal Sarhan, Haya Khaled Ali Abdulla AlKhalifa, Asal Buhasan, Abu Saleh Md Moin, Alexandra E. Butler
International Journal of Molecular Sciences.2023; 24(12): 9846. CrossRef
Association Between Trajectory of Severe Hypoglycemia and Dementia in Patients With Type 2 Diabetes: A Population-based Study
Chung-Yi Li, Chia-Lun Kuo, Ya-Hui Chang, Chin-Li Lu, Santi Martini, Wen-Hsuan Hou
Journal of Epidemiology.2022; 32(9): 423. CrossRef
Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976. CrossRef
Association between hypoglycemia and dementia in patients with diabetes: a systematic review and meta-analysis of 1.4 million patients
Lifen Huang, Manlian Zhu, Jie Ji
Diabetology & Metabolic Syndrome.2022;[Epub] CrossRef
Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
Sidharth Mehan, Sonalika Bhalla, Ehraz Mehmood Siddiqui, Nidhi Sharma, Ambika Shandilya, Andleeb Khan
Degenerative Neurological and Neuromuscular Disease.2022; Volume 12: 31. CrossRef
Immortal time bias for life-long conditions in retrospective observational studies using electronic health records
Freya Tyrer, Krishnan Bhaskaran, Mark J. Rutherford
BMC Medical Research Methodology.2022;[Epub] CrossRef
Glucose-lowering drugs, cognition, and dementia: The clinical evidence
Che-Yuan Wu, Lila Shapiro, Michael Ouk, Bradley J. MacIntosh, Sandra E. Black, Baiju R. Shah, Walter Swardfager
Neuroscience & Biobehavioral Reviews.2022; 137: 104654. CrossRef
Switching insulin degludec to insulin glulisine improved nocturnal hypoglycemia and ventricular arrythmia in an elderly type 1 diabetes patient with chronic heart failure: A case report
Yuriko Hajika, Yuji Kawaguchi, Takako Tanaka, Kenji Hamazaki, Yasuro Kumeda
Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics.2022; 59(2): 237. CrossRef
Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
Hanan Ehtewish, Abdelilah Arredouani, Omar El-Agnaf
International Journal of Molecular Sciences.2022; 23(11): 6144. CrossRef
Amyloid $$upbeta$$ (1–42) peptide impairs mitochondrial respiration in primary human brain microvascular endothelial cells: impact of dysglycemia and pre-senescence
Siva S. V. P. Sakamuri, Venkata N. Sure, Xiaoying Wang, Gregory Bix, Vivian A. Fonseca, Ricardo Mostany, Prasad V. G. Katakam
GeroScience.2022; 44(6): 2721. CrossRef
Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments
Premranjan Kumar, Jayshree Mishra, Narendra Kumar
Nutrients.2022; 14(18): 3715. CrossRef
Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?
Clémence Bussiere, Pauline Chauvin, Jean-Michel Josselin, Christine Sevilla-Dedieu
Health Economics Review.2022;[Epub] CrossRef
Fasting Glucose Variability and the Risk of Dementia in Individuals with Diabetes: A Nationwide Cohort Study
Da Young Lee, Jaeyoung Kim, Sanghyun Park, So Young Park, Ji Hee Yu, Ji A Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Kyungdo Han, Nan Hee Kim
Diabetes & Metabolism Journal.2022; 46(6): 923. CrossRef
Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
Katharina Mattishent, Yoon K. Loke
Frontiers in Endocrinology.2021;[Epub] CrossRef
Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks
Olga V. Saik, Vadim V. Klimontov
International Journal of Molecular Sciences.2021; 22(22): 12419. CrossRef
Muscle strength, an independent determinant of glycemic control in older adults with long-standing type 2 diabetes: a prospective cohort study
Bo Kyung Koo, Seoil Moon, Min Kyong Moon
BMC Geriatrics.2021;[Epub] CrossRef
Optimal Type 2 Diabetes Mellitus Management and Active Ageing
Alessia Maria Calabrese, Valeria Calsolaro, Sara Rogani, Chukwuma Okoye, Nadia Caraccio, Fabio Monzani
Endocrines.2021; 2(4): 523. CrossRef
Response: Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125–33)
Seung Jin Han
Diabetes & Metabolism Journal.2020; 44(2): 360. CrossRef
Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study
Francesco Zaccardi, Suping Ling, Claire Lawson, Melanie J. Davies, Kamlesh Khunti
Diabetologia.2020; 63(10): 2129. CrossRef
Letter: Hypoglycemia and Dementia Risk in Older Patients with Type 2 Diabetes Mellitus: A Propensity-Score Matched Analysis of a Population-Based Cohort Study (Diabetes Metab J 2020;44:125–33)
Jin Hwa Kim
Diabetes & Metabolism Journal.2020; 44(2): 356. CrossRef
Low‐glucose‐sensitive TRPC6 dysfunction drives hypoglycemia‐induced cognitive impairment in diabetes
Chengkang He, Peng Gao, Yuanting Cui, Qiang Li, Yingsha Li, Zongshi Lu, Huan Ma, Yu Zhao, Li Li, Fang Sun, Xiaowei Chen, Hongbo Jia, Daoyan Liu, Gangyi Yang, Hongting Zheng, Zhiming Zhu
Clinical and Translational Medicine.2020;[Epub] CrossRef
Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Niki Katsiki, Kalliopi Kotsa, Anca P. Stoian, Dimitri P. Mikhailidis
Current Pharmaceutical Design.2020; 26(43): 5637. CrossRef

Review

Others
Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications: Giacomo Cappon, Martina Vettoretti, Giovanni Sparacino, Andrea Facchinetti; Diabetes Metab J. 2019;43(4):383-397. Published online July 25, 2019; DOI: https://doi.org/10.4093/dmj.2019.0121

26,379 View
1,153 Download
203 Web of Science
209 Crossref

Abstract PDF PubReader

By providing blood glucose (BG) concentration measurements in an almost continuous-time fashion for several consecutive days, wearable minimally-invasive continuous glucose monitoring (CGM) sensors are revolutionizing diabetes management, and are becoming an increasingly adopted technology especially for diabetic individuals requiring insulin administrations. Indeed, by providing glucose real-time insights of BG dynamics and trend, and being equipped with visual and acoustic alarms for hypo- and hyperglycemia, CGM devices have been proved to improve safety and effectiveness of diabetes therapy, reduce hypoglycemia incidence and duration, and decrease glycemic variability. Furthermore, the real-time availability of BG values has been stimulating the realization of new tools to provide patients with decision support to improve insulin dosage tuning and infusion. The aim of this paper is to offer an overview of current literature and future possible developments regarding CGM technologies and applications. In particular, first, we outline the technological evolution of CGM devices through the last 20 years. Then, we discuss about the current use of CGM sensors from patients affected by diabetes, and, we report some works proving the beneficial impact provided by the adoption of CGM. Finally, we review some recent advanced applications for diabetes treatment based on CGM sensors.

Citations

Citations to this article as recorded by

Identifying and mapping measures of medication safety during transfer of care in a digital era: a scoping literature review
Catherine Leon, Helen Hogan, Yogini H Jani
BMJ Quality & Safety.2024; 33(3): 173. CrossRef
Highly sensitive and stable glucose sensing using N-type conducting polymer based organic electrochemical transistor
Gang Zhou, Zhu Cao, Yangxuan Liu, Haoyu Zheng, Kai Xu
Journal of Electroanalytical Chemistry.2024; 952: 117961. CrossRef
Effectiveness and User Perception of an In-Vehicle Voice Warning for Hypoglycemia: Development and Feasibility Trial
Caterina Bérubé, Vera Franziska Lehmann, Martin Maritsch, Mathias Kraus, Stefan Feuerriegel, Felix Wortmann, Thomas Züger, Christoph Stettler, Elgar Fleisch, A Baki Kocaballi, Tobias Kowatsch
JMIR Human Factors.2024; 11: e42823. CrossRef
Nafion based biosensors: a review of recent advances and applications
Roya Mohammadzadeh Kakhki
International Journal of Polymeric Materials and Polymeric Biomaterials.2024; 73(17): 1470. CrossRef
Can Electrochemical Aptasensors Achieve the Commercial Success of Glucose Biosensors?
Sina Ardalan, Anna Ignaszak
Advanced Sensor Research.2024;[Epub] CrossRef
Digital Health and Machine Learning Technologies for Blood Glucose Monitoring and Management of Gestational Diabetes
Huiqi Y. Lu, Xiaorong Ding, Jane E. Hirst, Yang Yang, Jenny Yang, Lucy Mackillop, David A. Clifton
IEEE Reviews in Biomedical Engineering.2024; 17: 98. CrossRef
Effects of Digitization of Self-Monitoring of Blood Glucose Records Using a Mobile App and the Cloud System on Outpatient Management of Diabetes: Single-Armed Prospective Study
Tomoko Handa, Takeshi Onoue, Tomoko Kobayashi, Ryutaro Maeda, Keigo Mizutani, Ayana Yamagami, Tamaki Kinoshita, Yoshinori Yasuda, Shintaro Iwama, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Yoshinori Az
JMIR Diabetes.2024; 9: e48019. CrossRef
The Association of Macronutrient Consumption and BMI to Exhaled Carbon Dioxide in Lumen Users: Retrospective Real-World Study
Shlomo Yeshurun, Tomer Cramer, Daniel Souroujon, Merav Mor
JMIR mHealth and uHealth.2024; 12: e56083. CrossRef
Generative adversarial network-based data augmentation for improving hypoglycemia prediction: A proof-of-concept study
Wonju Seo, Namho Kim, Sung-Woon Park, Sang-Man Jin, Sung-Min Park
Biomedical Signal Processing and Control.2024; 92: 106077. CrossRef
Pre‐dinner walks may be superior to post‐dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed‐loop insulin delivery systems
Lauren V. Turner, Michael C. Riddell
Diabetes, Obesity and Metabolism.2024; 26(6): 2492. CrossRef
Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on “time in range” in patients with type 2 diabetes
Yongru Chen, Jingxian Chen, Shuo Zhang, Dan Zhu, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin, Fengwu Chen, Yun Liang, Jiaxiong Zheng, Barkat Ali Khan, Kaijian Hou
Frontiers in Pharmacology.2024;[Epub] CrossRef
Advancements in nanohybrid material-based acetone gas sensors relevant to diabetes diagnosis: A comprehensive review
Arpit Verma, Deepankar Yadav, Subramanian Natesan, Monu Gupta, Bal Chandra Yadav, Yogendra Kumar Mishra
Microchemical Journal.2024; 201: 110713. CrossRef
Utility of Flash Glucose Monitoring to Determine Glucose Variation Induced by Different Doughs in Persons with Type 2 Diabetes
Maria Antonietta Taras, Sara Cherchi, Ilaria Campesi, Valentina Margarita, Gavino Carboni, Paola Rappelli, Giancarlo Tonolo
Diabetology.2024; 5(1): 129. CrossRef
Facile chemiresistive biosensor functionalized with PANI/GOx and novel green synthesized silver nanoparticles for glucose sensing
Jitendra B. Zalke, N.P. Narkhede, Dinesh R. Rotake, Shiv Govind Singh
Microchemical Journal.2024; 200: 110339. CrossRef
A novel questionnaire for evaluating digital tool use (DTUQ-D) among individuals with type 2 diabetes: exploring the digital landscape
Ora Peleg, Efrat Hadar, Meyran Boniel-Nissim
Frontiers in Public Health.2024;[Epub] CrossRef
Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial
Ji Yoon Kim, Sang-Man Jin, Kang Hee Sim, Bo-Yeon Kim, Jae Hyoung Cho, Jun Sung Moon, Soo Lim, Eun Seok Kang, Cheol-Young Park, Sin Gon Kim, Jae Hyeon Kim
Diabetologia.2024; 67(7): 1223. CrossRef
Global scientific trends on the islet transplantation in the 21st century: A bibliometric and visualized analysis
Sheng Chen, PeiZhong Wu, Ting Zhang, Jianqiang Zhang, Hongjun Gao
Medicine.2024; 103(17): e37945. CrossRef
A method for evaluating the risks of glucose dysregulation in daily life by continuous measurement of glucose excursions under reduced glycemic load: a pilot study
Yoshitada Katagiri, Hiromi Ozaku, Katsuhiko Kondo
Frontiers in Sensors.2024;[Epub] CrossRef
The Impact of Missing Continuous Blood Glucose Samples on Machine Learning Models for Predicting Postprandial Hypoglycemia: An Experimental Analysis
Najib Ur Rehman, Ivan Contreras, Aleix Beneyto, Josep Vehi
Mathematics.2024; 12(10): 1567. CrossRef
Measures of nutrition status and health for weight‐inclusive patient care: A narrative review
Kasuen Mauldin, Giselle A. P. Pignotti, John Gieng
Nutrition in Clinical Practice.2024; 39(4): 751. CrossRef
Long-Term Evaluation of Inserted Nanocomposite Hydrogel-Based Phosphorescent Oxygen Biosensors: Evolution of Local Tissue Oxygen Levels and Foreign Body Response
David Chimene, Waqas Saleem, Nichole Longbottom, Brian Ko, Ananth Soundaram Jeevarathinam, Staci Horn, Michael J. McShane
ACS Applied Bio Materials.2024; 7(6): 3964. CrossRef
Comparison of Metabolic Control in Children and Adolescents Treated with Insulin Pumps
Agnieszka Lejk, Karolina Myśliwiec, Arkadiusz Michalak, Barbara Pernak, Wojciech Fendler, Małgorzata Myśliwiec
Children.2024; 11(7): 839. CrossRef
Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung
Jochen Seufert, Ingrid Dänschel, Stefan Gölz, Nicola Haller, Bernhard Kulzer, Susanne Tan, Oliver Schnell, Tobias Wiesner, Jens Kroeger
Diabetologie und Stoffwechsel.2024;[Epub] CrossRef
The Influence of Nickel Electrode’s Morphology on Glucose Detection
Hailong Hu, Guohua Ma, Baogang Guo, Xingquan Zhang, Ruishi Xie, Haifeng Liu, Heyan Huang
Electrocatalysis.2024; 15(5): 374. CrossRef
Insertable Biosensors: Combining Implanted Sensing Materials with Wearable Monitors
David Chimene, Kirstie M.K. Queener, Brian S. Ko, Mike McShane, Michael Daniele
Annual Review of Biomedical Engineering .2024; 26(1): 197. CrossRef
Development and Effectiveness of a Pattern Management Educational Program Using Continuous Glucose Monitoring for Type 2 Diabetic Patients in Korea: A Quasi-Experimental Study
Seung-Yeon Kong, Mi-Kyoung Cho
Healthcare.2024; 12(14): 1381. CrossRef
Review of Microwave Near-Field Sensing and Imaging Devices in Medical Applications
Cristina Origlia, David O. Rodriguez-Duarte, Jorge A. Tobon Vasquez, Jean-Charles Bolomey, Francesca Vipiana
Sensors.2024; 24(14): 4515. CrossRef
Diabetes Management in Transition: Market Insights and Technological Advancements in CGM and Insulin Delivery
Tae Sang Yu, Soojeong Song, Junwoo Yea, Kyung‐In Jang
Advanced Sensor Research.2024;[Epub] CrossRef
How to Use Continuous Glucose Monitoring Efficiently in Diabetes Management: Opinions and Recommendations by German Experts on the Status and Open Questions
Andreas Thomas, Thomas Haak, Astrid Tombek, Bernhard Kulzer, Dominic Ehrmann, Olga Kordonouri, Jens Kröger, Oliver Schubert-Olesen, Ralf Kolassa, Thorsten Siegmund, Nicola Haller, Lutz Heinemann
Journal of Diabetes Science and Technology.2024;[Epub] CrossRef
Patterned thin film enzyme electrodes via spincoating and glutaraldehyde vapor crosslinking: towards scalable fabrication of integrated sensor-on-CMOS devices
Dvin Adalian, Xiomi Madero, Samson Chen, Musab Jilani, Richard D. Smith, Songtai Li, Christin Ahlbrecht, Juan Cardenas, Abhinav Agarwal, Azita Emami, Oliver Plettenburg, Peter A. Petillo, Axel Scherer
Lab on a Chip.2024; 24(17): 4172. CrossRef
Continuous Glucose, Insulin and Lifestyle Data Augmentation in Artificial Pancreas Using Adaptive Generative and Discriminative Models
Deepjyoti Kalita, Hrishita Sharma, Khalid B. Mirza
IEEE Journal of Biomedical and Health Informatics.2024; 28(8): 4963. CrossRef
Management of Continuous Glucose Monitors in Radiation Oncology Patients
Johnathan Zeng, Tara Kosak, Samir Malkani, Julie C. Hudson, Neil E. Martin, Roy B. Tishler, Itai M. Pashtan
Practical Radiation Oncology.2024;[Epub] CrossRef
Glycemic Outcomes and Nurse Perceptions of Continuous Glucose Monitoring for Hospitalized Patients
Alexandra Thullen, Rebecca Gerber, Alyson Keen
Journal of Nursing Care Quality.2024; 39(4): 310. CrossRef
Advances in Type 1 Diabetes Mellitus Management in Children
Mridu Bahal, Vineeta Pande, Jasleen Dua, Shailaja Mane
Cureus.2024;[Epub] CrossRef
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials
Martin Haluzík, Mohammed E. Al‐Sofiani, Alice Y. Y. Cheng, Felipe Lauand, Lydie Melas‐Melt, Julio Rosenstock
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Evaluating the Impact of Continuous Glucose Monitoring on Erectile Dysfunction in Type 1 Diabetes: A Focus on Reducing Glucose Variability and Inflammation
Nicola Tecce, Davide Menafra, Mattia Proganò, Mario Felice Tecce, Rosario Pivonello, Annamaria Colao
Healthcare.2024; 12(18): 1823. CrossRef
Development of a Novel Insulin Sensor for Clinical Decision-Making
Eva Vargas, Eleonora M. Aiello, Jordan E. Pinsker, Hazhir Teymourian, Farshad Tehrani, Mei Mei Church, Lori M. Laffel, Francis J. Doyle, Mary-Elizabeth Patti, Eyal Dassau, Joseph Wang
Journal of Diabetes Science and Technology.2023; 17(4): 1029. CrossRef
Diabetes technology and sexual health: which role?
V. Zamponi, J. Haxhi, G. Pugliese, A. Faggiano, R. Mazzilli
Journal of Endocrinological Investigation.2023; 47(6): 1315. CrossRef
Discordance Between Glycated Hemoglobin A1c and the Glucose Management Indicator in People With Diabetes and Chronic Kidney Disease
Philippe Oriot, Claire Viry, Antoine Vandelaer, Sébastien Grigioni, Malanie Roy, Jean Christophe Philips, Gaëtan Prévost
Journal of Diabetes Science and Technology.2023; 17(6): 1553. CrossRef
Expertenaustausch zum Einsatz von kontinuierlichem Glukosemonitoring (CGM) im Diabetesmanagement: Eine aktuelle Bestandsaufnahme und Blick in die Zukunft
Andreas Thomas, Thomas Haak, Astrid Tombek, Bernhard Kulzer, Dominic Ehrmann, Olga Kordonouri, Jens Kroeger, Oliver Schubert-Olesen, Ralf Kolassa, Thorsten Siegmund, Nicola Haller, Lutz Heinemann
Diabetologie und Stoffwechsel.2023; 18(01): 57. CrossRef
Evaluation of the performance and usability of a novel continuous glucose monitoring system
Li Yan, Qiang Li, Qingbo Guan, Mingsong Han, Yu Zhao, Junfei Fang, Jiajun Zhao
International Journal of Diabetes in Developing Countries.2023; 43(4): 551. CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park
Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Intermittent-scanned continuous glucose monitoring with low glucose alarms decreases hypoglycemia incidence in middle-aged adults with type 1 diabetes in real-life setting
Philippe Oriot, Michel P. Hermans
Journal of Diabetes and its Complications.2023; 37(2): 108385. CrossRef
Applications of Microwaves in Medicine
J.-C. Chiao, Changzhi Li, Jenshan Lin, Robert H. Caverly, James C. M. Hwang, Harel Rosen, Arye Rosen
IEEE Journal of Microwaves.2023; 3(1): 134. CrossRef
A Double-Needle Gold-Silver Electrodes Continuous Glucose Monitoring Device
C. Ben Ali Hassine, A. Tekin
IRBM.2023; 44(3): 100752. CrossRef
Accuracy of Flash Glucose Monitoring in Hemodialysis Patients With and Without Diabetes Mellitus
Michèle R. Weber, Matthias Diebold, Peter Wiesli, Andreas D. Kistler
Experimental and Clinical Endocrinology & Diabetes.2023; 131(03): 132. CrossRef
Minimally invasive electrochemical continuous glucose monitoring sensors: Recent progress and perspective
Yuanyuan Zou, Zhengkang Chu, Jiuchuan Guo, Shan Liu, Xing Ma, Jinhong Guo
Biosensors and Bioelectronics.2023; 225: 115103. CrossRef
Continuous Glucose Monitoring in Enterally Fed Children with Severe Central Nervous System Impairment
Marlena Górska, Joanna Kudzin, Anna Borkowska, Agnieszka Szlagatys-Sidorkiewicz, Agnieszka Szadkowska, Małgorzata Myśliwiec, Ewa Toporowska-Kowalska
Nutrients.2023; 15(3): 513. CrossRef
Prevalence of type 2 diabetes complications and its association with diet knowledge and skills and self‐care barriers in Tabriz, Iran: A cross‐sectional study
Habib Jalilian, Elnaz Javanshir, Leila Torkzadeh, Saeedeh Fehresti, Nazanin Mir, Majid Heidari‐Jamebozorgi, Somayeh Heydari
Health Science Reports.2023;[Epub] CrossRef
Status of continuous glucose monitoring use and management in tertiary hospitals of China: a cross-sectional study
Liping Chen, Xiaoqin Liu, Qin Lin, Hongmei Dai, Yong Zhao, Zumin Shi, Liping Wu
BMJ Open.2023; 13(2): e066801. CrossRef
Diboronic-Acid-Based Electrochemical Sensor for Enzyme-Free Selective and Sensitive Glucose Detection
Joong-Hyun Kim, Hongsik Choi, Chul-Soon Park, Heung-Seop Yim, Dongguk Kim, Sungmin Lee, Yeonkeong Lee
Biosensors.2023; 13(2): 248. CrossRef
Artificial intelligence biosensors for continuous glucose monitoring
Xiaofeng Jin, Andrew Cai, Tailin Xu, Xueji Zhang
Interdisciplinary Materials.2023; 2(2): 290. CrossRef
Continuous Glucose Monitoring in Dogs and Cats
Francesca Del Baldo, Federico Fracassi
Veterinary Clinics of North America: Small Animal Practice.2023; 53(3): 591. CrossRef
Accurate Post-Calibration Predictions for Noninvasive Glucose Measurements in People Using Confocal Raman Spectroscopy
Anders Pors, Kaspar G. Rasmussen, Rune Inglev, Nina Jendrike, Amalie Philipps, Ajenthen G. Ranjan, Vibe Vestergaard, Jan E. Henriksen, Kirsten Nørgaard, Guido Freckmann, Karl D. Hepp, Michael C. Gerstenberg, Anders Weber
ACS Sensors.2023; 8(3): 1272. CrossRef
Diabetes mellitus in der Akut- und Notfallmedizin
Leo Benning, Julian Krehl, Felix Patricius Hans
Notfallmedizin up2date.2023; 18(01): 45. CrossRef
Empowering People with Diabetes: Role of Continuous Glucose Monitor Systems
Sneha B Srivastava
American Journal of Lifestyle Medicine.2023; 17(3): 359. CrossRef
Diabétologie connectée : quelles sont les attentes des médecins et des patients ?
Nicolas Naïditch, Jean-Pierre Riveline
Médecine des Maladies Métaboliques.2023; 17(2): 2S3. CrossRef
Association of Vibrotactile Biofeedback With Reduced Ergonomic Risk for Surgeons During Tonsillectomy
Natalie A. Kelly, Abdulrahman Althubaiti, Aashika D. Katapadi, Adam G. Smith, Sarah C. Nyirjesy, Jane H. Yu, Amanda J. Onwuka, Tendy Chiang
JAMA Otolaryngology–Head & Neck Surgery.2023; 149(5): 397. CrossRef
The Evolution of Diabetes Technology – Options Toward Personalized Care
Maleeha Zahid, Samaneh Dowlatshahi, Abhishek H. Kansara, Archana R. Sadhu
Endocrine Practice.2023; 29(8): 653. CrossRef
A Personalized and Adaptive Insulin Bolus Calculator Based on Double Deep Q- Learning to Improve Type 1 Diabetes Management
Giulia Noaro, Taiyu Zhu, Giacomo Cappon, Andrea Facchinetti, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(5): 2536. CrossRef
Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems
Ntethelelo Sibiya, Bonisiwe Mbatha, Phikelelani Ngubane, Andile Khathi
Current Drug Delivery.2023; 20(6): 656. CrossRef
Machine Learning–Based Time in Patterns for Blood Glucose Fluctuation Pattern Recognition in Type 1 Diabetes Management: Development and Validation Study
Nicholas Berin Chan, Weizi Li, Theingi Aung, Eghosa Bazuaye, Rosa M Montero
JMIR AI.2023; 2: e45450. CrossRef
Drug Delivery Systems for Personal Healthcare by Smart Wearable Patch System
Bikram Khadka, Byeongmoon Lee, Ki-Taek Kim
Biomolecules.2023; 13(6): 929. CrossRef
Wearable Electrochemical Glucose Sensors in Diabetes Management: A Comprehensive Review
Tamoghna Saha, Rafael Del Caño, Kuldeep Mahato, Ernesto De la Paz, Chuanrui Chen, Shichao Ding, Lu Yin, Joseph Wang
Chemical Reviews.2023; 123(12): 7854. CrossRef
Real-life 24-week changes in glycemic parameters among European users of flash glucose monitoring with type 1 and 2 diabetes and different levels of glycemic control
Annel Lameijer, Julia J. Bakker, Kalvin Kao, Yongjin Xu, Rijk O.B. Gans, Henk J.G. Bilo, Timothy C. Dunn, Peter R. van Dijk
Diabetes Research and Clinical Practice.2023; 201: 110735. CrossRef
Les médicaments anti-diabétiques : ce que le médecin anesthésiste réanimateur doit savoir
Michael Joubert
Anesthésie & Réanimation.2023; 9(3): 251. CrossRef
Glycemia control using remote technologies
L. A. Suplotova, O. O. Alieva
Meditsinskiy sovet = Medical Council.2023; 17(9): 81. CrossRef
Data-enabled learning and control algorithms for intelligent glucose management: The state of the art
Deheng Cai, Wenjing Wu, Marzia Cescon, Wei Liu, Linong Ji, Dawei Shi
Annual Reviews in Control.2023; 56: 100897. CrossRef
A Markov Model of Gap Occurrence in Continuous Glucose Monitoring Data for Realistic in Silico Clinical Trials
Martina Vettoretti, Martina Drecogna, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Computer Methods and Programs in Biomedicine.2023; 240: 107700. CrossRef
Volumetric Electron Transfer from Metabolites to Chemically Doped Polymer Electrodes
Siew Ting Melissa Tan, Gijun Lee, Kalee Rozylowicz, Adam Marks, Alberto Salleo
Advanced Functional Materials.2023;[Epub] CrossRef
Diabetes and hypertension MobileHealth systems: a review of general challenges and advancements
Bliss Utibe-Abasi Stephen, Benedicta C. Uzoewulu, Phillip Michael Asuquo, Simeon Ozuomba
Journal of Engineering and Applied Science.2023;[Epub] CrossRef
THE ASSESSMENT OF COMPENSATION OF CARBOHYDRATE METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH METABOLIC SYNDROME BEYOND THE LIMITS OF GLYCATED HEMOGLOBIN
Taras V. Romaniv, Nadiya V. Skrypnyk, Ulyana V. Synko, Nataliia M. Voronych-Semchenko, Oleh V. Melnyk, Anna O. Hryb, Igor B. Boruchok
Wiadomości Lekarskie.2023; 76(6): 1385. CrossRef
Pros and cons of continous glucose monitoring
Marcin Ciechański, Edyta Witkowska, Agnieszka Ostańska, Adrianna Szafran, Klaudia Wiśniewska, Laura Piasek, Grzegorz Godek, Kacper Więcław, Katarzyna Stańko, Wiktor Terelak
Journal of Medical Science.2023;[Epub] CrossRef
Continuous Glucose Monitoring by Insulin-Treated Pilots Flying Commercial Aircraft Within the ARA.MED.330 Diabetes Protocol: A Preliminary Feasibility Study
Gillian L. Garden, Fariba Shojaee-Moradie, Ewan J. Hutchison, Brian M. Frier, Kenneth M. Shaw, Simon R. Heller, Gerd Koehler, Julia K. Mader, Declan Maher, Graham A. Roberts, David L. Russell-Jones
Diabetes Technology & Therapeutics.2023; 25(8): 543. CrossRef
Importance of continuous glucose monitoring in the treatment of diabetes mellitus
Sun Joon Moon, Won-Young Lee
Journal of the Korean Medical Association.2023; 66(7): 432. CrossRef
DiaTrend: A dataset from advanced diabetes technology to enable development of novel analytic solutions
Temiloluwa Prioleau, Abigail Bartolome, Richard Comi, Catherine Stanger
Scientific Data.2023;[Epub] CrossRef
Testing the Real-World Accuracy of the Dexcom G6 Pro CGM During the Insulin-Only Bionic Pancreas Pivotal Trial
Martin Chase Marak, Peter Calhoun, Edward R. Damiano, Steven J. Russell, Katrina J. Ruedy, Roy W. Beck
Diabetes Technology & Therapeutics.2023; 25(11): 817. CrossRef
Use of continuous glucose monitoring in pediatric gastroenterology allows for personalized nutrition support care – Potential for collaboration between pediatric endocrinologists and gastroenterologists
Kathryn Hitchcock, Stephanie Oliveira
Journal of Pediatric Endocrinology and Diabetes.2023; 3: 34. CrossRef
Anti-biofouling strategies for implantable biosensors of continuous glucose monitoring systems
Yan Zheng, Dunyun Shi, Zheng Wang
Frontiers of Chemical Science and Engineering.2023; 17(12): 1866. CrossRef
A novel strategy for therapeutic drug monitoring: application of biosensors to quantify antimicrobials in biological matrices
Quanfang Wang, Sihan Li, Jiaojiao Chen, Luting Yang, Yulan Qiu, Qian Du, Chuhui Wang, Mengmeng Teng, Taotao Wang, Yalin Dong
Journal of Antimicrobial Chemotherapy.2023; 78(11): 2612. CrossRef
Hypoglycemic Effect of an Herbal Decoction (Modified Gangsimtang) in a Patient with Severe Type 2 Diabetes Mellitus Refusing Oral Anti-Diabetic Medication: A Case Report
Sungjun Joo, Hyonjun Chun, Jisu Lee, Seungmin Seo, Jungmin Lee, Jungtae Leem
Medicina.2023; 59(11): 1919. CrossRef
GluGAN: Generating Personalized Glucose Time Series Using Generative Adversarial Networks
Taiyu Zhu, Kezhi Li, Pau Herrero, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(10): 5122. CrossRef
Millifluidic valves and pumps made of tape and plastic
Josue U. Amador-Hernandez, Pablo E. Guevara-Pantoja, Diana F. Cedillo-Alcantar, Gabriel A. Caballero-Robledo, Jose L. Garcia-Cordero
Lab on a Chip.2023; 23(20): 4579. CrossRef
Continuous glucose monitoring metrics following sub-Tenon’s injection of triamcinolone acetonide for diabetic macular edema
Rei Sotani-Ogawa, Sentaro Kusuhara, Yushi Hirota, Kyung Woo Kim, Wataru Matsumiya, Wataru Ogawa, Makoto Nakamura
Graefe's Archive for Clinical and Experimental Ophthalmology.2023;[Epub] CrossRef
Offline Deep Reinforcement Learning and Off-Policy Evaluation for Personalized Basal Insulin Control in Type 1 Diabetes
Taiyu Zhu, Kezhi Li, Pantelis Georgiou
IEEE Journal of Biomedical and Health Informatics.2023; 27(10): 5087. CrossRef
Flash Glucose Monitoring in Croatia: The Optimal Number of Scans per Day to Achieve Good Glycemic Control in Type 1 Diabetes
Silvija Canecki-Varzic, Ivana Prpic-Krizevac, Maja Cigrovski Berkovic, Dario Rahelic, Ema Schonberger, Marina Gradiser, Ines Bilic-Curcic
Medicina.2023; 59(11): 1893. CrossRef
The importance of interpreting machine learning models for blood glucose prediction in diabetes: an analysis using SHAP
Francesco Prendin, Jacopo Pavan, Giacomo Cappon, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti
Scientific Reports.2023;[Epub] CrossRef
SHMAD: A Smart Health Care System to Monitor Alzheimer’s Disease Patients
Shabana R. Ziyad, May Altulyan, Meshal Alharbi
Journal of Alzheimer's Disease.2023; 95(4): 1545. CrossRef
Séquelles fonctionnelles après résection pancréatique carcinologique. Un sujet d’actualité pour les patients et les praticiens
Andrea Mulliri, Michael Joubert, Marie-Astrid Piquet, Arnaud Alves, Benoît Dupont
Journal de Chirurgie Viscérale.2023; 160(6): 470. CrossRef
Functional sequelae after pancreatic resection for cancer
Andrea Mulliri, Michael Joubert, Marie-Astrid Piquet, Arnaud Alves, Benoît Dupont
Journal of Visceral Surgery.2023; 160(6): 427. CrossRef
Characteristics of glucose change in diabetes mellitus generalized through continuous wavelet transform processing: A preliminary study
Yoichi Nakamura, Shinya Furukawa
World Journal of Diabetes.2023; 14(10): 1562. CrossRef
Evaluating passive physiological data collection during Spravato treatment
Todd M. Solomon, Matus Hajduk, Martin Majernik, Jamileh Jemison, Alexander Deschamps, Jenna Scoggins, Adam Kolar, Miguel Amável Pinheiro, Peter Dubec, Ondrej Skala, Owen Muir, Amanda Tinkelman, Daniel R. Karlin, Robert Barrow
Frontiers in Digital Health.2023;[Epub] CrossRef
Fabrication of conductive Ag/AgCl/Ag nanorods ink on Laser-induced graphene electrodes on flexible substrates for non-enzymatic glucose detection
Rana Bagheri, Saeid Alikhani, Ebrahim Miri-Moghaddam
Scientific Reports.2023;[Epub] CrossRef
Co-design of Human-centered, Explainable AI for Clinical Decision Support
Cecilia Panigutti, Andrea Beretta, Daniele Fadda, Fosca Giannotti, Dino Pedreschi, Alan Perotti, Salvatore Rinzivillo
ACM Transactions on Interactive Intelligent Systems.2023; 13(4): 1. CrossRef
Analysis of blood glucose monitoring – a review on recent advancements and future prospects
Gayathri Priyadarshini R, Sathiya Narayanan
Multimedia Tools and Applications.2023; 83(20): 58375. CrossRef
Overview of modern sensors for continuous glucose monitoring
K. T. Momynaliev, M. V. Prokopiev, I. V. Ivanov
Diabetes mellitus.2023; 26(6): 575. CrossRef
A Prospective Multicenter Clinical Performance Evaluation of the C-CGM System
Mihailo Rebec, Kevin Cai, Ralph Dutt-Ballerstadt, Ellen Anderson
Journal of Diabetes Science and Technology.2022; 16(2): 390. CrossRef
Perceived Burdens and Benefits Associated With Continuous Glucose Monitor Use in Type 1 Diabetes Across the Lifespan
Vidita Divan, Margaret Greenfield, Christopher P. Morley, Ruth S. Weinstock
Journal of Diabetes Science and Technology.2022; 16(1): 88. CrossRef
Technologies for Diabetes Self-Monitoring: A Scoping Review and Assessment Using the REASSURED Criteria
Jessica Hanae Zafra-Tanaka, David Beran, Beatrice Vetter, Rangarajan Sampath, Antonio Bernabe-Ortiz
Journal of Diabetes Science and Technology.2022; 16(4): 962. CrossRef
Temporal Trends for Diabetes Management and Glycemic Control Between 2010 and 2019 in Korean Children and Adolescents with Type 1 Diabetes
Jaewon Choe, Seung Hyun Won, Yunsoo Choe, Sang Hee Park, Yun Jeong Lee, Jieun Lee, Young Ah Lee, Han Hyuk Lim, Jae-Ho Yoo, Seong Yong Lee, Eun Young Kim, Choong Ho Shin, Jae Hyun Kim
Diabetes Technology & Therapeutics.2022; 24(3): 201. CrossRef
International comparison of glycaemic control in people with type 1 diabetes: an update and extension
Regina Prigge, John A. McKnight, Sarah H. Wild, Aveni Haynes, Timothy W. Jones, Elizabeth A. Davis, Birgit Rami‐Merhar, Maria Fritsch, Christine Prchla, Astrid Lavens, Kris Doggen, Suchsia Chao, Ronnie Aronson, Ruth Brown, Else H. Ibfelt, Jannet Svensson,
Diabetic Medicine.2022;[Epub] CrossRef
Artificial intelligence perspective in the future of endocrine diseases
Mandana Hasanzad, Hamid Reza Aghaei Meybodi, Negar Sarhangi, Bagher Larijani
Journal of Diabetes & Metabolic Disorders.2022; 21(1): 971. CrossRef
Telehealth Technologies and Their Benefits to People With Diabetes
Chinenye O. Usoh, Kristine Kilen, Carolyn Keyes, Crystal Paige Johnson, Joseph A. Aloi
Diabetes Spectrum.2022; 35(1): 8. CrossRef
Acetylated Trifluoromethyl Diboronic Acid Anthracene with a Large Stokes Shift and Long Excitation Wavelength as a Glucose-Selective Probe
Hongsik Choi, Inhyeok Song, Chul Soon Park, Heung-seop Yim, Joong Hyun Kim
Applied Sciences.2022; 12(6): 2782. CrossRef
Suitability of the Unified Theory of Acceptance and Use of Technology 2 Model for Predicting mHealth Acceptance Using Diabetes as an Example: Qualitative Methods Triangulation Study
Patrik Schretzlmaier, Achim Hecker, Elske Ammenwerth
JMIR Human Factors.2022; 9(1): e34918. CrossRef
Continuous Glucose Monitoring System Based on Percutaneous Microneedle Array
Ming-Nan Chien, Yu-Jen Chen, Chin-Han Bai, Jung-Tung Huang
Micromachines.2022; 13(3): 478. CrossRef
Impact of COVID-19 Lockdown on the Metabolic Control Parameters in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
Ifan Ali Wafa, Nando Reza Pratama, Nurizzah Farahiyah Sofia, Elsha Stephanie Anastasia, Tiffany Konstantin, Maharani Ayuputeri Wijaya, M. Rifqi Wiyono, Lilik Djuari, Hermina Novida
Diabetes & Metabolism Journal.2022; 46(2): 260. CrossRef
Expert Roundtable on Continuous Glucose Monitoring
Cheryl Rosenfeld, Thomas Blevins, Grazia Aleppo, Gregory Forlenza, Diana Isaacs, Javier Morales, Jane Seley, Jeffrey Unger
Endocrine Practice.2022; 28(6): 622. CrossRef
Glucose variability and predicted cardiovascular risk after gastrectomy
Jun Shibamoto, Takeshi Kubota, Takuma Ohashi, Hirotaka Konishi, Atsushi Shiozaki, Hitoshi Fujiwara, Kazuma Okamoto, Eigo Otsuji
Surgery Today.2022; 52(11): 1634. CrossRef
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS
Tadej Battelino, Richard M Bergenstal, Angel Rodríguez, Laura Fernández Landó, Ross Bray, Zhentao Tong, Katelyn Brown
The Lancet Diabetes & Endocrinology.2022; 10(6): 407. CrossRef
Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes
Loïc Olçomendy, Louis Cassany, Antoine Pirog, Roberto Franco, Emilie Puginier, Manon Jaffredo, David Gucik-Derigny, Héctor Ríos, Alejandra Ferreira de Loza, Julien Gaitan, Matthieu Raoux, Yannick Bornat, Bogdan Catargi, Jochen Lang, David Henry, Sylvie Re
Frontiers in Endocrinology.2022;[Epub] CrossRef
Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: A systematic review and meta‐analysis of randomised controlled trials
Mona Elbalshy, Jillian Haszard, Hazel Smith, Sarahmarie Kuroko, Barbara Galland, Nick Oliver, Viral Shah, Martin I. de Bock, Benjamin J. Wheeler
Diabetic Medicine.2022;[Epub] CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Selection of Noninvasive Features in Wrist-Based Wearable Sensors to Predict Blood Glucose Concentrations Using Machine Learning Algorithms
Brian Bogue-Jimenez, Xiaolei Huang, Douglas Powell, Ana Doblas
Sensors.2022; 22(9): 3534. CrossRef
Generation of post-meal insulin correction boluses in type 1 diabetes simulation models for in-silico clinical trials: More realistic scenarios obtained using a decision tree approach
N. Camerlingo, M. Vettoretti, S. Del Favero, A. Facchinetti, P. Choudhary, G. Sparacino
Computer Methods and Programs in Biomedicine.2022; 221: 106862. CrossRef
A Miniaturized Optofluidic Glucose Monitoring System Based on Enzyme Colorimetry
Qingmei Xu, Chongwei Zou, Chengtao Sun, Xingguo Zhang, Haixia Yu, Dachao Li
IEEE Sensors Journal.2022; 22(10): 9246. CrossRef
Use and Trends of Diabetes Self-Management Technologies: A Correlation-Based Study
Jesús Fontecha, Iván González, Alfonso Barragán, Theodore Lim, Dario Pitocco
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Nanotechnology in Diabetes Mellitus: Overview for Nurses
R Priya, Baba Vajrala
Pondicherry Journal of Nursing.2022; 15(1): 22. CrossRef
Effect of Different Glucose Monitoring Methods on Bold Glucose Control: A Systematic Review and Meta-Analysis
Yeling Wang, Congcong Zou, Han Na, Weixin Zeng, Xiaoyan Li, Xi Lou
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Noninvasive Blood Glucose Monitoring Systems Using Near-Infrared Technology—A Review
Aminah Hina, Wala Saadeh
Sensors.2022; 22(13): 4855. CrossRef
Performance of islets of Langerhans conformally coated via an emulsion cross-linking method in diabetic rodents and nonhuman primates
Aaron A. Stock, Grisell C. Gonzalez, Sophia I. Pete, Teresa De Toni, Dora M. Berman, Alexander Rabassa, Waldo Diaz, James C. Geary, Melissa Willman, Joy M. Jackson, Noa H. DeHaseth, Noel M. Ziebarth, Anthony R. Hogan, Camillo Ricordi, Norma S. Kenyon, Ali
Science Advances.2022;[Epub] CrossRef
Review—Electrochemistry and Other Emerging Technologies for Continuous Glucose Monitoring Devices
Saroj Kumar Das, Kavya K. Nayak, P. R. Krishnaswamy, Vinay Kumar, Navakanta Bhat
ECS Sensors Plus.2022; 1(3): 031601. CrossRef
Design Strategies and Prospects in Developing Wearable Glucose Monitoring System Using Printable Organic Transistor and Microneedle: A Review
Fazliyatul Azwa Md Rezali, Norhayati Soin, Sharifah Fatmadiana Wan Muhamad Hatta, Mohamad Hazwan Mohd Daut, Muhammad Hafizuddin Al-Helmy Nouxman, Hanim Hussin
IEEE Sensors Journal.2022; 22(14): 13785. CrossRef
Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
Armaan Nallicheri, Katherine M Mahoney, Hanna A Gutow, Natalie Bellini, Diana Isaacs
Endocrinology.2022; 18(1): 27. CrossRef
Evaluation of Mesoporous TiO2 Layers as Glucose Optical Sensors
David Ortiz de Zárate, Sara Serna, Salvador Ponce-Alcántara, Jaime García-Rupérez
Sensors.2022; 22(14): 5398. CrossRef
A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
Alessandro Rossi, Annieke Venema, Petra Haarsma, Lude Feldbrugge, Rob Burghard, David Rodriguez-Buritica, Giancarlo Parenti, Maaike H Oosterveer, Terry G J Derks
The Journal of Clinical Endocrinology & Metabolism.2022; 107(9): e3612. CrossRef
Continuous glucose monitoring as a close to real life alternative to meal studies – a pilot study with a functional drink containing amino acids and chromium
Azat Samigullin, Per M. Humpert, Elin Östman
Frontiers in Medical Technology.2022;[Epub] CrossRef
An overview of recent advances in insulin delivery and wearable technology for effective management of diabetes
Sujeet Kumar Raj, M. Ravindra Babu, Sukriti Vishwas, M.V.N.L. Chaitanya, Vancha Harish, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua, Sachin Kumar Singh
Journal of Drug Delivery Science and Technology.2022; 75: 103728. CrossRef
Medical Certification of Pilots Through the Insulin-Treated Diabetes Mellitus Protocol at the FAA
Lynn K. Stanwyck, James R. DeVoll, Joyce Pastore, Zykevise Gamble, Anna Poe, Gabrielle V. Gui
Aerospace Medicine and Human Performance.2022; 93(8): 627. CrossRef
Rate of glycaemic control and associated factors in patients with type 2 diabetes mellitus treated with insulin-based therapy at selected hospitals in Northwest Ethiopia: a multicentre cross-sectional study
Ashenafi Kibret Sendekie, Eyayaw Ashete Belachew, Ephrem Mebratu Dagnew, Adeladlew Kassie Netere
BMJ Open.2022; 12(9): e065250. CrossRef
Glucose Profiles Assessed by Intermittently Scanned Continuous Glucose Monitoring System during the Perioperative Period of Metabolic Surgery
Kyuho Kim, Sung Hee Choi, Hak Chul Jang, Young Suk Park, Tae Jung Oh
Diabetes & Metabolism Journal.2022; 46(5): 713. CrossRef
Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia
Ashenafi Kibret Sendekie, Adeladlew Kassie Netere, Eyayaw Ashete Belachew, Rekha Samuel
PLOS ONE.2022; 17(9): e0275032. CrossRef
Continuous Glucose Monitoring for the Diagnosis of Gestational Diabetes Mellitus: A Pilot Study
Daria Di Filippo, Marrwah Ahmadzai, Melissa Han Yiin Chang, Ksana Horgan, Ru Min Ong, Justine Darling, Mahmood Akhtar, Amanda Henry, Alec Welsh, Daniela Foti
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Caring for people with diabetes
Martha M. Funnell, Katherine A. Kloss, Robin B. Nwankwo
Nursing.2022; 52(11): 26. CrossRef
Tackling the challenges of developing microneedle-based electrochemical sensors
Hilmee Abdullah, Tonghathai Phairatana, Itthipon Jeerapan
Microchimica Acta.2022;[Epub] CrossRef
A Concise and Systematic Review on Non-Invasive Glucose Monitoring for Potential Diabetes Management
Soumyasanta Laha, Aditi Rajput, Suvra S. Laha, Rohan Jadhav
Biosensors.2022; 12(11): 965. CrossRef
Assessment of Seasonal Stochastic Local Models for Glucose Prediction without Meal Size Information under Free-Living Conditions
Francesco Prendin, José-Luis Díez, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti, Jorge Bondia
Sensors.2022; 22(22): 8682. CrossRef
Wearable Sensor-Based Monitoring of Environmental Exposures and the Associated Health Effects: A Review
Xueer Lin, Jiaying Luo, Minyan Liao, Yalan Su, Mo Lv, Qing Li, Shenglan Xiao, Jianbang Xiang
Biosensors.2022; 12(12): 1131. CrossRef
Acceptability and feasibility of continuous glucose monitoring in people with diabetes: protocol for a mixed-methods systematic review of quantitative and qualitative evidence
Jennifer V. E. Brown, Ramzi Ajjan, Najma Siddiqi, Peter A. Coventry
Systematic Reviews.2022;[Epub] CrossRef
Utilization of Personalized Machine-Learning to Screen for Dysglycemia from Ambulatory ECG, toward Noninvasive Blood Glucose Monitoring
I-Min Chiu, Chi-Yung Cheng, Po-Kai Chang, Chao-Jui Li, Fu-Jen Cheng, Chun-Hung Richard Lin
Biosensors.2022; 13(1): 23. CrossRef
Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy
Rajesh Rajput, Suyasha Saini, Siddhant Rajput, Parankush Upadhyay
Indian Journal of Endocrinology and Metabolism.2022; 26(6): 537. CrossRef
GESTATIONAL DIABETES MELLITUS: MODERN GLYCEMIA MONITORING SYSTEMS
YU.A. DUDAREVA, V.A. GURYEVA, G.V. NEMTSEVA
AVICENNA BULLETIN.2022; 24(1): 97. CrossRef
Extraction With Sweat-Sebum Emulsion as a New Test Method for Leachables in Patch-Based Medical Devices, Illustrated by Assessment of Isobornylacrylate (IBOA) in Diabetes Products
Herbert Fink, Nuno M. de Barros Fernandes, Jörg Weissmann, Manfred Frey
Journal of Diabetes Science and Technology.2021; 15(4): 792. CrossRef
Mathematical Models of Meal Amount and Timing Variability With Implementation in the Type-1 Diabetes Patient Decision Simulator
Nunzio Camerlingo, Martina Vettoretti, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Journal of Diabetes Science and Technology.2021; 15(2): 346. CrossRef
Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience
Alan Godfrey, Benjamin Vandendriessche, Jessie P. Bakker, Cheryl Fitzer‐Attas, Ninad Gujar, Matthew Hobbs, Qi Liu, Carrie A. Northcott, Virginia Parks, William A. Wood, Vadim Zipunnikov, John A. Wagner, Elena S. Izmailova
Clinical and Translational Science.2021; 14(1): 62. CrossRef
Self-charging wearables for continuous health monitoring
Jiyong Kim, Salman Khan, Peng Wu, Sungjin Park, Hwanjoo Park, Choongho Yu, Woochul Kim
Nano Energy.2021; 79: 105419. CrossRef
Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices
Yannis Préau, Martine Armand, Sébastien Galie, Pauline Schaepelynck, Denis Raccah
Diabetes Technology & Therapeutics.2021; 23(4): 259. CrossRef
Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel
Sanjay Kalra, Shehla Shaikh, Gagan Priya, Manas P. Baruah, Abhyudaya Verma, Ashok K. Das, Mona Shah, Sambit Das, Deepak Khandelwal, Debmalya Sanyal, Sujoy Ghosh, Banshi Saboo, Ganapathi Bantwal, Usha Ayyagari, Daphne Gardner, Cecilia Jimeno, Nancy E. Barb
Diabetes Therapy.2021; 12(2): 465. CrossRef
Machine-Learning Based Model to Improve Insulin Bolus Calculation in Type 1 Diabetes Therapy
Giulia Noaro, Giacomo Cappon, Martina Vettoretti, Giovanni Sparacino, Simone Del Favero, Andrea Facchinetti
IEEE Transactions on Biomedical Engineering.2021; 68(1): 247. CrossRef
Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown
Federico Boscari, Sara Ferretto, Ambra Uliana, Angelo Avogaro, Daniela Bruttomesso
Nutrition & Diabetes.2021;[Epub] CrossRef
Technological innovation of Continuous Glucose Monitoring (CGM) as a tool for commercial aviation pilots with insulin-treated diabetes and stakeholders/regulators: A new chance to improve the directives?
F. Strollo, A. Furia, P. Verde, A. Bellia, M. Grussu, A. Mambro, M.D. Petrelli, S. Gentile
Diabetes Research and Clinical Practice.2021; 172: 108638. CrossRef
Machine Learning Techniques for Hypoglycemia Prediction: Trends and Challenges
Omer Mujahid, Ivan Contreras, Josep Vehi
Sensors.2021; 21(2): 546. CrossRef
Time in range–A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study
Marina Valenzano, Ivan Cibrario Bertolotti, Adriano Valenzano, Giorgio Grassi
BMJ Open Diabetes Research & Care.2021; 9(1): e001045. CrossRef
Machine learning for the diagnosis of early-stage diabetes using temporal glucose profiles
Woo Seok Lee, Junghyo Jo, Taegeun Song
Journal of the Korean Physical Society.2021; 78(5): 373. CrossRef
Forecasting of Glucose Levels and Hypoglycemic Events: Head-to-Head Comparison of Linear and Nonlinear Data-Driven Algorithms Based on Continuous Glucose Monitoring Data Only
Francesco Prendin, Simone Del Favero, Martina Vettoretti, Giovanni Sparacino, Andrea Facchinetti
Sensors.2021; 21(5): 1647. CrossRef
A “Slide Rule” to Adjust Insulin Dose Using Trend Arrows in Adults with Type 1 Diabetes: Test in Silico and in Real Life
Daniela Bruttomesso, Federico Boscari, Giuseppe Lepore, Giulia Noaro, Giacomo Cappon, Angela Girelli, Lutgarda Bozzetto, Andrea Tumminia, Giorgio Grassi, Giovanni Sparacino, Luigi Laviola, Andrea Facchinetti
Diabetes Therapy.2021; 12(5): 1313. CrossRef
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Marcela Martinez, Jimena Santamarina, Adrian Pavesi, Carla Musso, Guillermo E Umpierrez
BMJ Open Diabetes Research & Care.2021; 9(1): e002032. CrossRef
Hypoglycaemia detection and prediction techniques: A systematic review on the latest developments
Omar Diouri, Monika Cigler, Martina Vettoretti, Julia K. Mader, Pratik Choudhary, Eric Renard
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Smartphone-based colorimetric detection systems for glucose monitoring in the diagnosis and management of diabetes
Özlem Kap, Volkan Kılıç, John G. Hardy, Nesrin Horzum
The Analyst.2021; 146(9): 2784. CrossRef
The impact of hypoglycaemia on the quality of life of family members of adults with type 1 or type 2 diabetes: A qualitative systematic review
Mette Valdersdorf Jensen, Melanie Broadley, Jane Speight, Alison Scope, Louise Preston, Simon Heller, Bastiaan E. de Galan, Frans Pouwer, Christel Hendrieckx
Diabetic Medicine.2021;[Epub] CrossRef
A review of biosensor technology and algorithms for glucose monitoring
Yaguang Zhang, Jingxue Sun, Liansheng Liu, Hong Qiao
Journal of Diabetes and its Complications.2021; 35(8): 107929. CrossRef
Optical glucose biosensor built-in disposable strips and wearable electronic devices
Abdullah Reda, Sherif A. El-Safty, Mahmoud M. Selim, Mohamed A. Shenashen
Biosensors and Bioelectronics.2021; 185: 113237. CrossRef
Advances, Challenges, and Cost Associated with Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes
Karishma A. Datye, Daniel R. Tilden, Angelee M. Parmar, Eveline R. Goethals, Sarah S. Jaser
Current Diabetes Reports.2021;[Epub] CrossRef
Is HbA1c an ideal biomarker of well-controlled diabetes?
Georgia Kaiafa, Stavroula Veneti, George Polychronopoulos, Dimitrios Pilalas, Stylianos Daios, Ilias Kanellos, Triantafyllos Didangelos, Stamatina Pagoni, Christos Savopoulos
Postgraduate Medical Journal.2021; 97(1148): 380. CrossRef
Technology in the management of type 2 diabetes: Present status and future prospects
Aideen Daly, Roman Hovorka
Diabetes, Obesity and Metabolism.2021; 23(8): 1722. CrossRef
A Non-Invasive Flexible Glucose Monitoring Sensor Using a Broadband Reject Filter
Moussa Bteich, Jessica Hanna, Joseph Costantine, Rouwaida Kanj, Youssef Tawk, Ali H. Ramadan, Assaad A. Eid
IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology.2021; 5(2): 139. CrossRef
Wearable patch delivery system for artificial pancreas health diagnostic-therapeutic application: A review
Nur Farrahain Nadia Ahmad, Nik Nazri Nik Ghazali, Yew Hoong Wong
Biosensors and Bioelectronics.2021; 189: 113384. CrossRef
Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies
Mary Katherine Ray, Alana McMichael, Maria Rivera-Santana, Jacob Noel, Tamara Hershey
JMIR Diabetes.2021; 6(2): e27027. CrossRef
Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 Diabetes
Magdalena M. Samojlik, Cherie L. Stabler
Acta Biomaterialia.2021; 133: 87. CrossRef
Evaluation of a continuous glucose monitoring system in neonatal foals
David Wong, Caitlin Malik, Katarzyna Dembek, Krista Estell, Megan Marchitello, Katie Wilson
Journal of Veterinary Internal Medicine.2021; 35(4): 1995. CrossRef
Flash Glucose Monitoring in the Netherlands: Increased monitoring frequency is associated with improvement of glycemic parameters
Annel Lameijer, Nicole Lommerde, Timothy C. Dunn, Marion J. Fokkert, Mireille A. Edens, Kalvin Kao, Yongjin Xu, R.O.B. Gans, Henk J.G. Bilo, Peter R. van Dijk
Diabetes Research and Clinical Practice.2021; 177: 108897. CrossRef
Utilisation, access and recommendations regarding technologies for people living with type 1 diabetes: consensus statement of the ADS/ADEA/APEG/ADIPS Working Group
Anthony J Pease, Sofianos Andrikopoulos, Mary B Abraham, Maria E Craig, Brett Fenton, Jane Overland, Sarah Price, David Simmons, Glynis P Ross
Medical Journal of Australia.2021; 215(10): 473. CrossRef
Catalytic effects of magnetic and conductive nanoparticles on immobilized glucose oxidase in skin sensors
Lilian C Alarcón-Segovia, Amay J Bandodkar, John A Rogers, Ignacio Rintoul
Nanotechnology.2021; 32(37): 375101. CrossRef
Optical Glucose Sensor Using Pressure Sensitive Paint
Jongwon Park
Sensors.2021; 21(13): 4474. CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu
Science.2021; 373(6554): 522. CrossRef
Clinical Utilities of Continuous Glucose Monitoring and Insulin Pumps in Pediatric Patients with Type 1 Diabetes
Jieun Lee, Jae Hyun Kim
The Ewha Medical Journal.2021; 44(3): 55. CrossRef
Personalized Postprandial Glucose Response–Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes
Orly Ben-Yacov, Anastasia Godneva, Michal Rein, Smadar Shilo, Dmitry Kolobkov, Netta Koren, Noa Cohen Dolev, Tamara Travinsky Shmul, Bat Chen Wolf, Noa Kosower, Keren Sagiv, Maya Lotan-Pompan, Niv Zmora, Adina Weinberger, Eran Elinav, Eran Segal
Diabetes Care.2021; 44(9): 1980. CrossRef
Lack of Acceptance of Digital Healthcare in the Medical Market: Addressing Old Problems Raised by Various Clinical Professionals and Developing Possible Solutions
Jong Il Park, Hwa Young Lee, Hyunah Kim, Jisan Lee, Jiwon Shinn, Hun-Sung Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study §
Yannis Préau, Sébastien Galie, Pauline Schaepelynck, Martine Armand, Denis Raccah
Sensors.2021; 21(18): 6131. CrossRef
A Hybrid Automata Approach for Monitoring the Patient in the Loop in Artificial Pancreas Systems
Aleix Beneyto, Vicenç Puig, B. Wayne Bequette, Josep Vehi
Sensors.2021; 21(21): 7117. CrossRef
Editors’ Choice—Review—From Polarography to Electrochemical Biosensors: The 100-Year Quest for Selectivity and Sensitivity
William R. Heineman, Peter T. Kissinger, Kenneth R. Wehmeyer
Journal of The Electrochemical Society.2021; 168(11): 116504. CrossRef
Digital health and diabetes: experience from India
Jothydev Kesavadev, Gopika Krishnan, Viswanathan Mohan
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110546. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Sun Joon Moon, Inha Jung, Cheol-Young Park
Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef
Factors Associated with Adherence to Self-Monitoring of Blood Glucose Among Young People with Type 1 Diabetes in China: A Cross-Sectional Study
Wencong Lv, Jiaxin Luo, Qing Long, Jundi Yang, Xin Wang, Jia Guo
Patient Preference and Adherence.2021; Volume 15: 2809. CrossRef
Continuous glucose monitoring devices: A brief presentation (Review)
Doina Mihai, Diana Stefan, Daniela Stegaru, Georgiana Bernea, Ileana Vacaroiu, Toma Papacocea, Mircea Lupușoru, Adriana Nica, Ovidiu Stiru, Dorin Dragos, Octavian Olaru
Experimental and Therapeutic Medicine.2021;[Epub] CrossRef
Acute glycemic variability on admission predicts the prognosis in hospitalized patients with coronary artery disease: a meta-analysis
Zhaokun Pu, Lihong Lai, Xishan Yang, Yanyu Wang, Pingshuan Dong, Dan Wang, Yingli Xie, Zesen Han
Endocrine.2020; 67(3): 526. CrossRef
Glycemic profile of women with normoglycemia and gestational diabetes mellitus during early pregnancy using continuous glucose monitoring system
Charandeep Singh, Yashdeep Gupta, Alpesh Goyal, Mani Kalaivani, Vineeta Garg, Juhi Bharti, Seema Singhal, Garima Kachhawa, Vidushi Kulshrestha, Rajesh Kumari, Reeta Mahey, Jai B Sharma, Neerja Bhatla, Rajesh Khadgawat, Nandita Gupta, Nikhil Tandon
Diabetes Research and Clinical Practice.2020; 169: 108409. CrossRef
Efficacy of Intermittently Scanned Continuous Glucose Monitoring in the Prevention of Recurrent Severe Hypoglycemia
Timothy M.E. Davis, Penny Dwyer, Michelle England, P. Gerry Fegan, Wendy A. Davis
Diabetes Technology & Therapeutics.2020; 22(5): 367. CrossRef
How was the Diabetes Metabolism Journal added to MEDLINE?
Hye Jin Yoo
Science Editing.2020; 7(2): 201. CrossRef
Applying Nanomaterials to Modern Biomedical Electrochemical Detection of Metabolites, Electrolytes, and Pathogens
Itthipon Jeerapan, Thitaporn Sonsa-ard, Duangjai Nacapricha
Chemosensors.2020; 8(3): 71. CrossRef
Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies
Jason Li, Jia Y. Liang, Steven J. Laken, Robert Langer, Giovanni Traverso
Trends in Chemistry.2020; 2(4): 319. CrossRef
A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies
Sémah Tagougui, Nadine Taleb, Laurent Legault, Corinne Suppère, Virginie Messier, Inès Boukabous, Azadeh Shohoudi, Martin Ladouceur, Rémi Rabasa-Lhoret
Diabetologia.2020; 63(11): 2282. CrossRef
Bimetallic PtAu alloy nanomaterials for nonenzymatic selective glucose sensing at low potential
Lingling Lin, Shaohuang Weng, Yanjie Zheng, Xiyao Liu, Shaoming Ying, Feng Chen, Donghong You
Journal of Electroanalytical Chemistry.2020; 865: 114147. CrossRef
Type 1 Diabetes in Youth and Technology-Based Advances in Management
Christopher Ferber, Catherine S. Mao, Jennifer K. Yee
Advances in Pediatrics.2020; 67: 73. CrossRef
Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors
Martina Vettoretti, Giacomo Cappon, Andrea Facchinetti, Giovanni Sparacino
Sensors.2020; 20(14): 3870. CrossRef
Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active‐controlled, randomized, double‐blind study with open‐label extension (the EVERGREEN study)
Gyuri Kim, Soo Lim, Hyuk‐Sang Kwon, Ie B. Park, Kyu J. Ahn, Cheol‐Young Park, Su K. Kwon, Hye S. Kim, Seok W. Park, Sin G. Kim, Min K. Moon, Eun S. Kim, Choon H. Chung, Kang S. Park, Mikyung Kim, Dong J. Chung, Chang B. Lee, Tae H. Kim, Moon‐Kyu Lee
Diabetes, Obesity and Metabolism.2020; 22(9): 1527. CrossRef
Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
Jee Hee Yoo, Min Sun Choi, Jiyeon Ahn, Sung Woon Park, Yejin Kim, Kyu Yeon Hur, Sang-Man Jin, Gyuri Kim, Jae Hyeon Kim
Diabetes Technology & Therapeutics.2020; 22(10): 768. CrossRef
A New Approach to Determining Liquid Concentration Using Multiband Annular Ring Microwave Sensor and Polarity Correlator
Waleed Sethi, Ahmed Ibrahim, Khaled Issa, Ali Albishi, Saleh Alshebeili
Electronics.2020; 9(10): 1616. CrossRef
Estrategia terapéutica en el paciente diabético (I). Empoderamiento del paciente y formación. Objetivos terapéuticos. Estilo de vida, alimentación, vacunación y consejos al paciente diabético
F.B. Rivas Sánchez, J. Sanz Cánovas, J. Martín Carmona, S. Jansen Chaparro
Medicine - Programa de Formación Médica Continuada Acreditado.2020; 13(17): 943. CrossRef
Current status of continuous glucose monitoring among Korean children and adolescents with type 1 diabetes mellitus
Jae Hyun Kim
Annals of Pediatric Endocrinology & Metabolism.2020; 25(3): 145. CrossRef
Towards sensor-based calving detection in the rangelands: a systematic review of credible behavioral and physiological indicators
Anita Z Chang, David L Swain, Mark G Trotter
Translational Animal Science.2020;[Epub] CrossRef
Electrochemical glucose sensors in diabetes management: an updated review (2010–2020)
Hazhir Teymourian, Abbas Barfidokht, Joseph Wang
Chemical Society Reviews.2020; 49(21): 7671. CrossRef
An analytical approach to determine the optimal duration of continuous glucose monitoring data required to reliably estimate time in hypoglycemia
Nunzio Camerlingo, Martina Vettoretti, Andrea Facchinetti, Giovanni Sparacino, Julia K. Mader, Pratik Choudhary, Simone Del Favero
Scientific Reports.2020;[Epub] CrossRef
Smartphone-Based Data Collection in Ophthalmology
Florian Philipp Raber, Rokas Gerbutavicius, Armin Wolf, Karsten Kortüm
Klinische Monatsblätter für Augenheilkunde.2020; 237(12): 1420. CrossRef
Glycemic Status Assessment by the Latest Glucose Monitoring Technologies
Ilaria Malandrucco, Benedetta Russo, Fabiana Picconi, Marika Menduni, Simona Frontoni
International Journal of Molecular Sciences.2020; 21(21): 8243. CrossRef
Medical Nutrition Therapy Using Continuous Glucose Monitoring System
Mee Ra Kweon
The Journal of Korean Diabetes.2020; 21(4): 216. CrossRef
Use of Flash Glucose Monitoring in Patients on Intensive Insulin Treatment
Jun Sung Moon
The Journal of Korean Diabetes.2020; 21(4): 184. CrossRef
Data Analysis and Accuracy Evaluation of a Continuous Glucose-Monitoring Device
Lijun Cai, Wancheng Ge, Zhigang Zhu, Xueling Zhao, Zhanhong Li
Journal of Sensors.2019; 2019: 1. CrossRef
Development of an Error Model for a Factory-Calibrated Continuous Glucose Monitoring Sensor with 10-Day Lifetime
Martina Vettoretti, Cristina Battocchio, Giovanni Sparacino, Andrea Facchinetti
Sensors.2019; 19(23): 5320. CrossRef

Original Articles

Clinical Diabetes & Therapeutics
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice: A Ram Hong, Bo Kyung Koo, Sang Wan Kim, Ka Hee Yi, Min Kyong Moon; Diabetes Metab J. 2019;43(5):590-606. Published online February 28, 2019; DOI: https://doi.org/10.4093/dmj.2018.0134

7,493 View
121 Download
20 Web of Science
20 Crossref

Abstract PDF Supplementary Material PubReader

Background

This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.

Methods

We included 410 patients who started SGLT2 inhibitors (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between February 2015 and June 2017. The primary efficacy endpoint was a change in glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints were patients achieving HbA1c <7.0% and changes in the fasting plasma glucose (FPG), lipid profiles, body weight, and blood pressure (BP).

Results

The mean HbA1c at baseline was 8.5% (8.6% in the add-on group and 8.4% in the switch group). At week 12, the mean adjusted HbA1c decreased by −0.68% in the overall patients (P<0.001), by −0.94% in the add-on group, and by −0.42% in the switch group. Significant reductions in FPG were also observed both in the add-on group and switch group (−30.3 and −19.8 mg/dL, respectively). Serum triglyceride (−16.5 mg/dL), body weight (−2.1 kg), systolic BP (−4.7 mm Hg), and diastolic BP (−1.3 mm Hg) were significantly improved in the overall patients. Approximately 18.3% of the patients achieved HbA1c <7.0% at week 12. A low incidence of hypoglycemia and genital tract infection was observed (6.3% and 2.2%, respectively).

Conclusion

SGLT2 inhibitors can be a suitable option as either add-on or switch therapy for Korean patients with inadequately controlled T2DM.

Citations

Citations to this article as recorded by

Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus
Yesol Hong, Yoomin Jeon, Yoona Choi, Tae Kyu Chung, Howard Lee
Diabetes Therapy.2024; 15(2): 487. CrossRef
Real-world assessment of effectiveness and safety profile of remogliflozin etabonate in management of type 2 diabetes mellitus
Bipin Sethi, Subhankar Chowdhury, Supratik Bhattacharya, Sagar Katare, Sachin Suryawanshi, Hanmant Barkate
International Journal of Diabetes in Developing Countries.2023; 43(2): 214. CrossRef
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study
Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee
Diabetes, Obesity and Metabolism.2023; 25(9): 2743. CrossRef
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
Diabetes & Metabolism Journal.2023; 47(6): 808. CrossRef
Real-world Data of Glycemic Control in a Suburban Population in Northern India during the COVID-19 Pandemic
Jaydip V. Revale, Preeti J. Revale
International Journal of Diabetes and Technology.2023; 2(2): 60. CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas
Irish Journal of Medical Science (1971 -).2022; 191(4): 1647. CrossRef
Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
Nauman Wazir, Shafqat Ur Rehman
Journal of Gandhara Medical and Dental Science.2022; 9(1): 24. CrossRef
Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh, John‐Michael Gamble
Diabetic Medicine.2022;[Epub] CrossRef
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
Yonsei Medical Journal.2022; 63(9): 825. CrossRef
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data
Ha Young Jang, In-Wha Kim, Jung Mi Oh
Frontiers in Pharmacology.2022;[Epub] CrossRef
Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
Ai-Yu Yang, Hung-Chun Chen
International Journal of Clinical Pharmacy.2021; 43(4): 1015. CrossRef
Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, Huiling Feng, Xiaobao Wei, Xiaoyan Wu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 227. CrossRef
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial
Hiroaki Seino
Diabetes Therapy.2021; 12(3): 863. CrossRef
Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study
Min-Kyung Lee, Bongsung Kim, Kyungdo Han, Jae-Hyuk Lee, Minhee Kim, Mee Kyoung Kim, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon, Young-Jung Roh
Diabetes Care.2021; 44(10): 2419. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians
Muhammad Afzal, Fahad Al-Abbasi, Muhammad Nadeem, Sultan Alshehri, Mohammed Ghoneim, Syed Imam, Waleed Almalki, Imran Kazmi
Metabolites.2021; 11(11): 794. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Diabetes & Metabolism Journal.2020; 44(4): 489. CrossRef
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Kidney Research and Clinical Practice.2020; 39(3): 269. CrossRef
Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
Jung-Fu Chen, Yun-Shing Peng, Chung-Sen Chen, Chin-Hsiao Tseng, Pei-Chi Chen, Ting-I Lee, Yung-Chuan Lu, Yi-Sun Yang, Ching-Ling Lin, Yi-Jen Hung, Szu-Ta Chen, Chieh-Hsiang Lu, Chwen-Yi Yang, Ching-Chu Chen, Chun-Chuan Lee, Pi-Jung Hsiao, Ju-Ying Jiang, S
PeerJ.2020; 8: e9998. CrossRef
Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus
Maria Mirabelli, Eusebio Chiefari, Patrizia Caroleo, Raffaella Vero, Francesco Saverio Brunetti, Domenica Maria Corigliano, Biagio Arcidiacono, Daniela Patrizia Foti, Luigi Puccio, Antonio Brunetti
Journal of Diabetes Research.2019; 2019: 1. CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578. CrossRef

Clinical Care/Education
Patient Understanding of Hypoglycemia in Tertiary Referral Centers: Nan Hee Cho, Nam Kyung Kim, Eugene Han, Jun Hwa Hong, Eon Ju Jeon, Jun Sung Moon, Mi Hae Seo, Ji Eun Lee, Hyun-Ae Seo, Mi-Kyung Kim, Hye Soon Kim; Diabetes Metab J. 2018;42(1):43-52. Published online February 23, 2018; DOI: https://doi.org/10.4093/dmj.2018.42.1.43

5,319 View
78 Download
5 Web of Science
5 Crossref

Abstract PDF PubReader

Background

Hypoglycemia is an important complication in the treatment of patients with diabetes. We surveyed the insight by patients with diabetes into hypoglycemia, their hypoglycemia avoidance behavior, and their level of worry regarding hypoglycemia.

Methods

A survey of patients with diabetes, who had visited seven tertiary referral centers in Daegu or Gyeongsangbuk-do, Korea, between June 2014 and June 2015, was conducted. The survey contained questions about personal history, symptoms, educational experience, self-management, and attitudes about hypoglycemia.

Results

Of 758 participants, 471 (62.1%) had experienced hypoglycemia, and 250 (32.9%) had experienced hypoglycemia at least once in the month immediately preceding the study. Two hundred and forty-two (31.8%) of the participants had received hypoglycemia education at least once, but only 148 (19.4%) knew the exact definition of hypoglycemia. Hypoglycemic symptoms identified by the participants were dizziness (55.0%), sweating (53.8%), and tremor (40.8%). They mostly chose candy (62.1%), chocolate (37.7%), or juice (36.8%) as food for recovering hypoglycemia. Participants who had experienced hypoglycemia had longer duration of diabetes and a higher proportion of insulin usage. The mean scores for hypoglycemia avoidance behavior and worry about hypoglycemia were 21.2±10.71 and 23.38±13.19, respectively. These scores tended to be higher for participants with higher than 8% of glycosylated hemoglobin, insulin use, and experience of emergency room visits.

Conclusion

Many patients had experienced hypoglycemia and worried about it. We recommend identifying patients that are anxious about hypoglycemia and educating them about what to do when they develop hypoglycemic symptoms, especially those who have a high risk of hypoglycemia.

Citations

Citations to this article as recorded by

Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976. CrossRef
Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
Soo-Yeon Choi, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2021; 36(2): 263. CrossRef
Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes
Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Hyung-Wook Kim, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko
Scientific Reports.2021;[Epub] CrossRef
Response: Patient Understanding of Hypoglycemia in Tertiary Referral Centers (Diabetes Metab J 2018;42:43-52)
Nan Hee Cho, Hye Soon Kim
Diabetes & Metabolism Journal.2018; 42(2): 175. CrossRef
Letter: Patient Understanding of Hypoglycemia in Tertiary Referral Centers (Diabetes Metab J 2018;42:43-52)
Jae-Han Jeon
Diabetes & Metabolism Journal.2018; 42(2): 173. CrossRef

First
Prev
Page of 3
Next
Last

Search